FemTech Mid 2026 : Future Landscape, IPO Pipeline, Capital Trends & AI Threats Executive Summary FemTech is undergoing its most consequential structural shift since the term was coined in 2016. What began as a cycle-tracking utility is maturing into a precision medicine category spanning hormonal intelligence, AI-powered diagnostics, cardiometabolic care, longevity platforms and regulated medical devices. The global market, valued at approximately USD $9.12 to $9.78 Billion in 2025, is projected to reach USD $10.67 Billion in 2026 and expand to USD $18.98 to 41.14 Billion by 2031–2034 depending on the scope of the estimate, maintaining a CAGR of 14.2%–18.4%. A record USD $2.6 Billion in VC investment flowed into women's health in 2024, a 55% year-over-year increase, yet the sector still represents only approximately 2% of total healthcare venture capital, signalling a structural funding gap that remains investable. The 2026–2027 window is defined by converging forces: an IPO-ready cohort of capital-intensive platforms, private equity appetite for scalable B2B models, a deepening IP landscape, and a double-edged AI revolution that simultaneously empowers and threatens the sector's incumbents. Market Trajectory: From Wellness App to Clinical Infrastructure The fundamental transformation in FemTech is directional: from passive tracking to active clinical infrastructure. In 2025, the industry saw rapid evolution of AI-powered fertility and hormone-tracking technologies, with fertility platforms expanding beyond ovulation prediction to offer multi-hormone modelling, thyroid interplay analysis and metabolic pattern detection. The most defining commercial change is the pivot from volatile Direct-to-Consumer (D2C) subscription models to stable B2B corporate integration, a transition validated by Maven Clinic's USD $1.7 Billion valuation, achieved by demonstrating 2:1 clinical ROI through reduction of costly NICU stays and C-sections. The sector is also shedding its narrow reproductive focus. Conditions that disproportionately affect women, cardiovascular disease, autoimmune disorders, osteoporosis, are being drawn into the FemTech orbit, expanding total addressable market significantly. Women's health startup funding in 2024 grew from approximately USD $1.7 Billion in 2023 to USD $2.6 Billion, a performance 32 percentage points above total healthtech funding, which contracted over the same period. Emerging Niche Sub-Markets (2026–2027 Horizon) The following verticals are displaying the clearest signs of capital momentum, unmet clinical need and scalable business model formation: 1. Menopause & Longevity Tech By 2030, more than one billion women will be in perimenopause or menopause globally. Menopause has evolved from symptom-logging into integrated care platforms offering telehealth, AI-based flare-up prediction, non-hormonal therapy, and longitudinal data for cardiovascular and cognitive risk assessment. Companies like Midi Health and Alloy are scaling aggressively to capture the 75% of women seeking midlife care previously excluded from mainstream healthcare. The hormonal health app market alone is projected to reach USD $13 Billion, driven by rising demand for bone density, cardiovascular and cognitive wellbeing management through midlife. 2. Pelvic Health & Neuromodulation What began with consumer-grade Kegel trainers has evolved into clinically validated neuromodulation devices and AI-assisted pelvic floor diagnostic systems. Sword Health's pelvic health expansion, as part of its unified "AI Care" platform integrating musculoskeletal, women's health, mental health, and cardiometabolic care, exemplifies the hybridisation of this space. Sensor-enabled pelvic floor trainers are now being paired with clinical evidence for conditions including stress urinary incontinence, chronic pelvic pain, and postpartum recovery, meeting CE marking and FDA clearance requirements that create genuine regulatory moats. 3. Vaginal & Reproductive Microbiome Diagnostics At-home metagenomic testing is emerging as one of the most defensible and data-rich niches in FemTech. Companies like Evvy (vaginal microbiome sequencing) and Daye (diagnostic CBD tampons with microbiome analysis) are detecting conditions such as endometriosis, PCOS and bacterial vaginosis before clinical presentation. The convergence of DTC collection kits, cloud-based bioinformatics pipelines and actionable telehealth follow-up creates compound defensibility: proprietary biomarker datasets, patented assay methods and clinical validation locked inside subscription models. 4. Women's Cardiometabolic & Autoimmune Health Cardiovascular disease is the leading cause of premature death in women, yet sex-specific presentations remain dramatically understudied. This creates one of the clearest "white space" opportunities in FemTech. Similarly, autoimmune conditions, Lupus, rheumatoid arthritis, Hashimoto’s, affect women at two to three times the rate of men. AI-driven platforms trained on female-specific biological signals (hormonal cyclicity, inflammatory biomarkers, metabolic patterns) are beginning to address diagnostic delay, which averages 4 years longer for women across 770 diseases. In 2024, autoimmune and cardiovascular women's health received the smallest share of the record USD $2.6 Bn funding wave, making it the most underserved and therefore most attractive emerging category. 5. GLP-1 & Metabolic Health for Women Maven Clinic's launch of a GLP-1 care programme specifically calibrated for women's metabolic health, incorporating PCOS, perimenopause, and insulin resistance rather than BMI alone, signals a major sub-market. The intersection of the GLP-1 revolution with women's endocrinology creates an entirely new clinical niche: metabolic health management that accounts for hormonal cyclicity, fertility goals, and cardiovascular risk stratification unique to female biology. 6. Menstrual Diagnostics & Liquid Biopsy Menstrual blood is increasingly viewed as an information-rich biofluid. Startups are developing non-invasive diagnostic tools using menstrual fluid for biomarker detection of endometriosis, fibroids and cervical cancer, conditions that collectively affect hundreds of millions of women and are currently diagnosed through invasive procedures. This niche converges with broader point-of-care diagnostics trends and has clear regulatory and IP pathway clarity given its basis in established in vitro diagnostic frameworks. 7. Mental Health with Female Biological Context Mood disorders, anxiety, and postnatal depression are not gender-neutral conditions. Emerging platforms are beginning to integrate hormonal cycle data, sleep biomarkers, and cortisol proxies from wearables to contextualise mental health fluctuations biologically, moving beyond generic CBT apps toward truly cycle-aware digital therapeutics. This sub-niche benefits from high engagement, recurring subscription economics and a growing evidence base in psychoneuroendocrinology. 2026–2027 IPO Pipeline The 2026–2027 IPO window has been shaped by a "tale of two markets" from 2025, where mega-deals (USD $100M+) accounted for 42% of all digital health funding and total U.S. digital health venture funding reached USD $14.2 Billion, a 35% increase over 2024. The IPO pipeline is dominated by companies that have navigated the "Series B gap" and achieved sovereign scale through enterprise partnerships. The table below profiles the leading candidates: Company Sector Latest Est. Valuation Key IPO Signal Expected Window Maven Clinic Virtual Women's & Family Clinic USD $1.35 Bn+ D2C launch + GLP-1 programme for women 2026 Flo Health FemTech App (AI-driven) USD $1.2 Bn First pure-digital women's health unicorn; menopause expansion 2026/2027 Kindbody Fertility / Hybrid Clinics USD $1.8 Bn (2023) Series E-1/E-2 capital expansion; 300+ clinic network 2027 Ro D2C Telehealth / GLP-1 USD $7.19 Bn GLP-1 pivot + Novo Nordisk distribution deal 2026 Sword Health AI Care / Pelvic / MSK USD $4.0 Bn 10M AI sessions; unified women's health + MSK platform 2026/2027 Carrot Fertility Fertility Benefits USD $611 M Cigna partnership; global employer scale 2027 Oura Wearables / Health OS USD $11.0 Bn B2B corporate wellness; reproductive health insights 2026/2027 Maven Clinic has established itself as the world's largest virtual clinic for women's and family health, partnering with over 2,000 employers and health plans globally and has demonstrated a 27% reduction in NICU stays, translating to 4x combined clinical and business savings for enterprise partners. Flo Health, Europe's first femtech unicorn following its USD $200M Series C from General Atlantic in July 2024, supports 70 Million monthly active users and ~5 Million paid subscribers, with bookings expected to have exceeded USD $200M in 2024, a ~50% year-over-year increase. A dual-listing or primary US debut is considered likely by analysts to access deeper liquidity. Kindbody represents the hybrid model, combining tech-enabled portals with a physical clinic network, with vertical integration capturing the entire value chain from provider to employer benefit administrator. The performance of existing public peers sets important context. Hims & Hers, after peaking above USD $70 in early 2025, shed 75% of its value following FDA scrutiny of compounded GLP-1 drugs, before rebounding 40% on a landmark distribution agreement with Novo Nordisk, underscoring that "regulatory stability" is now the most valued currency in public market femtech valuations. Progyny reported record revenue exceeding USD $1.3 Billion in 2025 but saw its stock drop 21% early in 2026 on EPS miss and execution risk concerns, signalling that public investors demand consistent unit economics, not just top-line scale. Venture Capital Investment Trends Capital Concentration and the Mega-Deal Dynamic VC in femtech has undergone structural transformation. The "easy money" era has been replaced by extreme late-stage concentration: in 2025, while total deal value increased, actual deal count dropped by 5%, confirming that investors are backing proven winners rather than seeding new entrants. Deals exceeding USD 100M accounted for 42% of all 2025 digital health funding, and firms like Andreessen Horowitz (a16z), General Catalyst, and Kleiner Perkins participated in the majority of mega-deals. For early-stage founders, Series A capital is increasingly coming from specialist funds rather than generalist VC. Rise of Specialist FemTech Funds The emergence of dedicated women's health funds is materially reshaping deal access and sector intelligence: Fund HQ Focus Area Amboy Street Ventures USA Women's & Sexual Health (Seed/Series A) Goddess Gaia Ventures UK Fertility, Oncology, Chronic Disease RH Capital USA Reproductive Health & Health Equity Calm/Storm Ventures Austria "Tabootech" & Diverse Founding Teams Unconventional Ventures Denmark Scalable Impact Tech / Diverse Founders Avestria Ventures USA Life Sciences & Female-Led MedTech In 2021, 90% of senior investment professionals in healthcare VC were male, a structural bias that systematically discounted femtech deal flow. The growing presence of women as check-writers is improving sector-level diligence quality and reducing the "comfort bias" that historically directed capital away from women's health. The AI Premium AI has become the primary driver of investor appetite, with 54% of all 2025 funding dollars flowing to AI-enabled platforms. In femtech, this manifests in two ways: (1) clinical precision, where AI-driven biomarkers and molecular diagnostics enable hyper-personalised preventative care; and (2) operational efficiency, where AI co-pilots for clinical documentation and revenue cycle management are generating measurable ROI for payers, with some systems reporting USD 13,000 in additional revenue per clinician. An AI premium of approximately 19% on average deal size was documented in 2025, a figure expected to increase as agentic AI workflows enter clinical use. European Momentum Europe now accounts for approximately 20% of global femtech companies, with USD 28 billion in total femtech company valuations in 2024. European Series A valuations for femtech startups are 20–30% lower than comparable US digital health companies, presenting structurally attractive entry points. The European femtech market hit €2.4 billion in 2024 and is projected to reach €9.7 billion by 2033 at ~17% CAGR. Regulatory frameworks such as Germany's DiGA and France's PECAN reimbursement pathway are creating validated, scalable GTM routes for evidence-based digital health solutions. Private Equity: The Scalable, Sustainable and Defensible Model Thesis Private equity is entering femtech via a distinct investment thesis from VC: it is seeking mature, revenue-generating platforms with clinical ROI proof, sticky B2B distribution (employer benefits, NHS/payer integration), and hardware/software combination models that resist commoditisation. Global PE deployment reached USD 905 billion in 2025, a 57% year-on-year increase in Q4, with 80% of GPs expecting acquisition activity to increase further in 2026. PE funds in life sciences historically favour medical device, diagnostics, and SaaS companies already generating revenue, and are pursuing platform acquisition strategies with buy-and-build roll-up mandates. Femtech businesses that meet the "scalable, sustainable, and defensible" model criteria share four structural characteristics: 1. B2B anchoring — Revenue from employer health plans, NHS/payer contracts, or clinical network agreements provides the recurring, auditable cash flows PE underwriters require 2. Clinical validation — RCT-backed outcomes data transforms a "wellness app" into a reimbursable digital therapeutic with defensible margin structure 3. Vertical integration — Controlling the care pathway from diagnostics through treatment and follow-up (as Kindbody does across fertility) creates network effects and switching costs 4. Proprietary data assets — Longitudinal, sex-specific health datasets that train proprietary AI models are non-replicable assets that underpin valuation premium at exit Investment in women's health research delivers approximately 40x economic returns, as documented by Women's Health Access Matters in January 2026, a multiplier few sectors can approach. PE firms focused on healthcare services and digital health are increasingly recognising this structural inefficiency. The FemTech IP Stack Intellectual property in femtech is multi-layered, and the most defensible companies are building across all four layers simultaneously: Layer 1: Hardware Patents Device architectures, sensor assemblies, wearable form factors, biofluid collection mechanisms, and electrode configurations represent the most durable IP assets. These cover physical innovations that are difficult to design around and create direct barriers to clinical-grade market entry. Examples include the Oura Ring's 0.13°C temperature detection precision for hormonal mapping, or Elvie's breast pump mechanics. Layer 2: Signal Processing & Algorithm Patents AI/ML pipelines, signal processing methodologies for cycle and hormone prediction, pattern recognition for endometriosis imaging, and contraction detection algorithms can qualify for patent protection when they produce a concrete technical effect and are anchored to specific hardware components, avoiding the "abstract algorithm" ineligibility challenge under both UK and US patent law. For computer-implemented inventions, eligibility requires demonstrating improvement in computer function or a tangible, practical application with real-world technical value. Layer 3: Diagnostic Method Patents & Data Diagnostic methods (biomarker assays, metagenomic sequencing protocols, at-home collection methodologies) are patentable in the US and UK, though method-of-treatment claims face different eligibility standards across jurisdictions. Proprietary clinical datasets, particularly longitudinal, sex-specific data on hormonal patterns, menstrual biomarkers, and reproductive health trajectories, are not themselves patentable but generate irreplaceable competitive moats when used to train validated AI models. Layer 4: Brand & Trust Assets (Trademarks) In a sector where intimate health data is handled by consumer-facing products, brand equity and trust are material financial assets. Registered trademarks protect brand identifiers across distribution channels, facilitate e-commerce platform takedown enforcement, and signal credibility to enterprise procurement teams and institutional investors. For companies distributing internationally, the Madrid Protocol enables single-filing international trademark protection, essential for European femtech companies targeting US, UK, and APAC markets simultaneously. FemTech Mid 2026 : Future Landscape, IPO Pipeline, Capital Trends & AI Threats IP Strategy Priorities for Femtech Founders File patent applications before any public disclosure, conference presentation, or marketing activity — public disclosure before filing forfeits rights in most non-US jurisdictions Conduct freedom-to-operate searches early, particularly in pelvic health, fertility tracking, and wearable diagnostics, the most contested patent territories Build a global PCT portfolio from inception, particularly targeting the US, UK, EU, and key APAC markets In the EU context, map AI systems against EU AI Act risk categories now, AI systems intended as medical devices are classified as high-risk, triggering obligations around risk management, data governance, human oversight, and conformity assessments before market placement AI as Both Enabler and Structural Threat to FemTech AI is the defining force shaping femtech's next three years, simultaneously its most powerful growth driver and its most significant existential risk. AI as Enabler Machine learning models now forecast ovulation with precision surpassing traditional calendar methods; AI-enabled platforms assess contraction patterns and distinguish false labour; pattern recognition algorithms applied to imaging data offer earlier endometriosis detection; AI-driven genomic platforms identify mutations linked to breast and ovarian cancers. Natural Cycles processes more than 20 Million temperature readings daily and maintains 98% effectiveness when used correctly. Flo Health's AI models analyse more than 70 symptoms and life events. The transition from reactive tracking to predictive, proactive care, anticipating health outcomes before symptom onset, is the clearest near-term value creation vector in the sector. Threat 1: General-Purpose AI Disintermediation The most structurally significant threat is the integration of health intelligence into general-purpose AI platforms. OpenAI's launch of ChatGPT Health, Google/DeepMind's MedGemma, and Anthropic's expanded clinical and administrative AI capabilities represent a shift from health as a "speculative AI use case" to a "core product category for the most powerful AI platforms". These systems can interpret labs, summarise records, generate patient-facing health guidance, and support clinical documentation, at zero marginal cost, potentially disintermediating the information-provision layer of femtech apps. The structural vulnerability is acute for companies whose primary value proposition is symptom logging, health education, or general health information. Femtech founders face the risk of their top-of-funnel being absorbed into a general-purpose interface that does not charge for health queries. The strategic response is to move irreversibly toward clinical-grade, device-anchored and longitudinally validated offerings that general AI cannot replicate, proprietary biomarker data, regulated medical device status, payer relationships, and outcomes-linked contracts. Threat 2: Biased Training Data & the Male Default AI models learn from historical medical data, and that data runs on a male default. Women are diagnosed on average 4 years later than men across 770+ diseases. AI systems trained on this skewed dataset will systematically under-serve women, potentially at scale, unless femtech companies invest in female-specific, clinically validated datasets as their primary competitive moat. The NHS's experience with pulse oximeters that produced inaccurate readings for darker-skinned patients demonstrates precisely how embedded bias causes systemic harm. Threat 3: EU AI Act Compliance Burden From August 2026, the EU AI Act's high-risk obligations become fully applicable to AI systems intended as medical devices, including the majority of clinical-facing femtech AI. This introduces requirements around risk management systems, data governance for training datasets, technical documentation, human oversight mechanisms, accuracy requirements, conformity assessments, and for general-purpose AI model integrations, additional obligations around copyright compliance and incident reporting. Companies integrating third-party LLMs (e.g., using OpenAI or Anthropic APIs to power health assistants) must ensure that third-party contracts clearly allocate compliance responsibilities. UK femtech companies targeting EU users face regulatory divergence: the UK's sector-led, principles-based AI framework (MHRA + ICO led) differs from the EU's risk-categorised statutory regime, requiring compliance programmes flexible enough to accommodate both. Threat 4: Reproductive Data Security & Legal Exposure Post the 2022 US Supreme Court Dobbs decision, reproductive health data has been sought in law enforcement investigations in US states restricting abortion. Femtech companies that transfer data to US-based processors must apply rigorous data minimisation, ensure GDPR-compliant transfer mechanisms, and be transparent with users about circumstances in which data might be disclosed. Privacy failures, including prior security incidents at both Flo and Glow, remain a material ESG and valuation risk for the sector. The ICO's January 2026 Tech Futures report specifically flagged purpose creep, autonomous decision-making liability, and inferred special category data as critical risk domains for AI-enabled femtech. Threat 5: Margin Compression from Pharmaceutical Giants Companies like Hims & Hers and Ro that built high-margin businesses on compounded GLP-1 formulations now face margin compression as FDA enforcement drives them toward lower-margin, authorised pharmaceutical distribution agreements with Novo Nordisk and Eli Lilly. For femtech companies building GLP-1-adjacent offerings, the competitive dynamics of branded pharmaceutical distribution will structurally cap gross margins in ways that affect IPO-stage valuation multiples. Strategic Implications for M&A and Investment Positioning The convergence of maturing clinical platforms, a PE-rich dealmaking environment, and genuine IP defensibility creates a clear acquisition landscape in 2026–2027: Most attractive acquiree profiles for strategic buyers: Menopause platforms with >2 years of longitudinal user data and validated biomarker algorithms Diagnostic microbiome and at-home testing businesses with CE-marked or FDA-cleared kits and proprietary assay IP Pelvic health companies with regulated device status, clinical RCT data, and NHS/payer reimbursement pathways B2B employer-benefit platforms with multi-year enterprise contracts and demonstrable clinical cost-savings data Strategic acquirers most likely to be active: Large pharmaceutical companies (AstraZeneca, Roche, Novo Nordisk) seeking DTC women's health data assets to complement drug portfolios MedTech majors (Hologic, Becton Dickinson, Illumina) seeking diagnostics platform acquisitions in women's health Insurance groups and managed care organisations seeking embedded digital health solutions with proven ROI Big Tech health divisions (Apple Health, Google Health, Amazon Health Services) seeking proprietary women's health datasets and clinical validation to strengthen AI health platforms The closing of the women's health gap is quantifiably the most capital-efficient investment in global healthcare: every USD $350 Million invested in women's health research generates USD $14 Billion in economic returns, a 40x multiplier. With PE dry powder at a record USD $1.6 Trillion in secondaries alone, and 80% of GPs expecting increased acquisition activity in 2026, femtech's most defensible, scalable, and clinically validated businesses are entering the most favourable exit environment in the sector's history. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

2026 CNBC Disruptor 50 List: Healthcare Technology stands out as one of the strongest themes Healthcare technology stands out as one of the strongest themes in the 2026 CNBC Disruptor 50, but it is now framed almost entirely through an AI and data infrastructure lens rather than classic digital health point solutions. Below are the key takeaways specifically relevant to healthcare and health-adjacent tech. Dominance of AI-Native Infrastructure CNBC highlights that 43 of the 50 companies explicitly identify AI as core to their disruptive strategy, making AI the default operating layer across sectors including healthcare. The topline narrative is that value creation is concentrating in foundational and horizontal AI platforms (Anthropic, OpenAI, Databricks, etc.), which then power domain-specific applications in areas like diagnostics, care coordination, and payer/provider tooling. Healthcare as a Secondary but Critical Use Case The methodology piece notes that many Disruptor 50 companies are not labeled “healthcare” but have healthcare as one of their primary application domains (e.g., data platforms, workflow AI, security and infra tools that sell into health systems and payers). This reinforces a shift from pure-play digital health brands towards cross-vertical tech (AI infra, cybersecurity, data clouds, automation platforms) that monetise healthcare as a high-value vertical rather than a standalone category. Continued Presence of Care Delivery and Patient Platforms CNBC’s criteria specifically calls out healthcare as a focus area, and the 2026 list maintains representation of care delivery and patient-platform disruptors, including oncology care coordination platforms such as Thyme Care. These companies emphasise risk-bearing models, partnerships with payers/employers and measurable reductions in total cost of care, very much aligned with value-based care economics. Oncology and High-Acuity Care as Beachheads Thyme Care’s inclusion underscores oncology as a leading beachhead for tech-enabled care, with platforms taking financial accountability for outcomes and cost in partnership with payers and risk-bearing providers. The framing is less about “tele-oncology” and more about end-to-end oncology navigation, data-driven risk stratification, and closed-loop coordination across providers, payers, and patients. AI-First Clinical and Operational Intelligence The selection methodology stresses that scoring favoured companies with defensible data moats and AI-driven products, explicitly mentioning health-related applications among the verticals assessed. For healthcare, this means preference for businesses that embed AI into core workflows (triage, prediction, routing, coding, utilisation management) rather than offering bolt-on analytics or generic dashboards. Geographic Gravity: Bay Area AI, Global Healthcare Deployment 18 of the 50 companies are in the Bay Area, with 14 headquartered in San Francisco, and nearly half of all companies are based in California. For healthcare buyers in Europe and other regions, this implies that critical AI tooling for future healthtech stacks is largely being built in the Bay Area but will be distributed globally across payers, providers, and life science partners. Capital Concentration and Scale Expectations CNBC notes that the 2026 cohort collectively represents about 2.4 trillion dollars in valuation and 337 billion dollars in funding, nearly triple the funding base of the prior year. The top five AI platforms alone account for close to 2 trillion dollars of that value, which sets a high bar for healthcare-native startups and pushes many healthtech plays towards partnering with or building on these AI “super majors.” Implications for Healthcare and HealthTech Strategy The list signals that future healthcare disruption is expected to come from: AI-native infra providers expanding into healthcare, Risk-bearing care platforms in oncology and other high-cost conditions, and Data and workflow companies that can prove cost and outcome impact in payer–provider networks. Source: https://www.cnbc.com/2026/05/19/2026-cnbc-disruptor-50-rankings-full-list-companies.html 2026 CNBC Disruptor 50 List: Healthcare Technology stands out as one of the strongest themes Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Alcidion Expands Patient Flow Platform With Telstra Health Kyra Acquisition The Transaction Alcidion Group (ASX: ALC) signed an Asset Sale Agreement on 16th May 2026 to acquire three Kyra patient flow products from Telstra Health: Kyra Patient Flow Manager, Kyra Queue Manager, and Kyra IQ. The upfront cash consideration is $3.0 Million, funded from Alcidion's existing cash reserves of $15.1 Million (no debt as of 31st March 2026), with a further earn-out of up to $1.0 Million tied to recurring revenue thresholds over 12 months post-completion. Completion is expected by end of June 2026. What Kyra Does The Kyra suite is a proprietary set of digital solutions addressing patient flow and data access across hospital inpatient and outpatient settings: Kyra Patient Flow Manager – real-time oversight of a patient's hospital journey from admission to discharge Kyra Queue Manager – outpatient queuing and appointment flow management Kyra IQ – business intelligence and operational analytics, enabling near real-time performance insights to support proactive decision-making The platform integrates data from Patient Administration Systems, pathology, radiology, EMRs, and diet systems into a unified bed management and journey board interface. Deal Economics Metric Value Upfront consideration $3.0M AUD Earn-out potential Up to $1.0M AUD FY26 forecast revenue $3.7M AUD Recurring revenue share >90% FY26 forecast EBITDA ~$1.1M AUD Implied EBITDA multiple 2.7x The deal is projected to be earnings accretive from completion, given the 2.7x EBITDA multiple and the high proportion of sticky, recurring product revenue. Strategic Rationale for Alcidion This is a classic tuck-in acquisition that delivers several compounding benefits: Geographic expansion: Extends Alcidion's footprint into Queensland (where Kyra products dominate among Hospital & Health Services), plus new sites in Victoria, Western Australia, and Tasmania — both public and private sector Net-new customer base: Of the ~33 acquired customers, only two are existing Alcidion clients, immediately expanding its installed base Customer tenure: The top 10 customers average a ~10-year relationship, indicating deep clinical workflow integration and low churn risk Cloud migration runway: CEO Kate Quirke flagged the opportunity to transition Kyra customers from legacy on-premise systems onto Alcidion's modern cloud-enabled Miya Precision platform UK relevance: The deal also strengthens Alcidion's position in the UK, where its Miya Flow product is already deployed under the NHS G-Cloud framework at £385,000 per unit per year Competitive Context Alcidion is positioning itself as the leading enterprise patient flow provider across Australia, New Zealand, and the UK. Its Miya Precision platform (comprising Miya Flow, Miya Access, and Miya Command) already serves major health systems including Alfred Health in Melbourne and NHS Trusts in England and Scotland. The Kyra acquisition consolidates what had been a competitive product set under a single ownership structure, reducing fragmentation in the ANZ market and removing a Telstra Health-branded alternative from the landscape. M&A Angle From an investment banking perspective, the deal structure is notable for its discipline: a 2.7x EBITDA entry multiple with >90% recurring revenues is highly attractive for a SaaS-adjacent healthcare IT asset, and the earn-out mechanism aligns vendor incentives with post-close performance. Telstra Health's decision to divest Kyra, while retaining its broader health IT portfolio, reflects a broader rationalisation trend among telco-owned health subsidiaries that have struggled to compete with pure-play digital health specialists. For Alcidion, this fits a consolidator strategy in a fragmented ANZ HealthTech market, complementing its earlier Novari Health partnership for waitlist and referral management. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Strategic Analysis of the ResMed and Oura Partnership: Bridging Consumer Wearables and Clinical Sleep Medicine On May 19th, 2026, ResMed (NYSE: RMD, ASX: RMD), a prominent global health technology company specialising in sleep, breathing and home-delivered respiratory care and ŌURA, the manufacturer of the leading smart ring, announced a strategic partnership. This cross-industry collaboration represents a structured initiative to connect daily consumer wellness tracking with professional medical diagnostic and treatment networks. By linking Oura's passive biometric telemetry with ResMed's established clinical software and device ecosystem, the partnership seeks to systematically address the persistent diagnostic gap in Obstructive Sleep Apnea (OSA). In the United States alone, approximately 80% of individuals with OSA remain undiagnosed and untreated, posing a massive clinical challenge and creating a significant commercial opportunity for out-of-hospital care systems. This partnership emerges at a time of rapid transformation in the consumer health technology sector, where sleep monitoring has moved from a novel trend to an essential component of clinical preventive medicine. This shift is supported by epidemiological data indicating a rise in sleep disorders, driven by an aging global population and climbing obesity rates. Furthermore, legislative momentum, such as the Supplemental Oxygen Access Reform (SOAR) bill, which seeks to improve patient access to respiratory therapists and liquid oxygen, highlights a broader regulatory focus on optimising home-based respiratory support. Simultaneously, initiatives like the Main Street Competition Coalition, established by the National Community Pharmacists Association (NCPA) and the National Grocers Association (NGA), underscore the shifting dynamics of community-level healthcare distribution, where accessible health screening is increasingly decentralised. Technical Architecture and Wearable Biometrics The core of the partnership relies on translating passive, consumer-grade biometric tracking into clinically actionable events. The Oura Ring Gen3 and Oura Ring 4 collect near-continuous physiological data using advanced photoplethysmography (PPG) sensors, skin temperature sensors, and multi-axial accelerometers. The Oura Ring 4, utilising its proprietary Smart Sensing platform, increases the number of available signal pathways from eight to eighteen compared to previous generations, dynamically adapting to the user’s finger to optimise signal capture and battery efficiency. This architecture delivers a 120% improvement in blood oxygen saturation signal quality, resulting in a 30% increase in overnight average measurement accuracy and a 15% more accurate estimation of the Breathing Disturbance Index (BDI). Unlike standard smartwatches worn on the wrist, the finger-worn ring form factor benefits from closer arterial proximity, reducing motion artifacts and light pollution. In clinical validation studies comparing consumer sleep trackers (CSTs) with the gold standard of in-lab polysomnography (PSG) which simultaneously records electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), respiratory effort, nasal airflow, snoring, heart rate and body movement, wearables have demonstrated variable performance. For instance, a multi centre study assessing 11 commercially available CSTs, including the Google Pixel Watch, Galaxy Watch 5, Fitbit Sense 2, Apple Watch 8, Oura Ring 3, and nearable devices like the Withings Sleep Tracking Mat, revealed significant differences in sleep stage classification. Wearable devices often show a proportional bias in sleep efficiency metrics, while nearables exhibit higher bias in sleep latency measurements. Specifically, the Oura Ring's four-stage sleep classification algorithm has demonstrated a 79% accuracy rate when validated against polysomnography, establishing it as one of the most reliable consumer-grade trackers tested. The monitoring framework deployed under this partnership operates on a graduated notification scale. Within the Oura app, users can view their overnight breathing disturbances visualised as a timeline indicating "Optimal," "Fair," or "Pay Attention" states. Occasional minor disturbances are common and typically represent movement or positional changes, characterised by sparse blue lines on the app’s graphic interface alongside a normal average range of 95% to 100%. However, frequent, dense clusters of breathing disturbances paired with overnight oxygen desaturation drops below 90% trigger critical notifications, signalling potential sleep-disordered breathing and prompting the user to explore clinical evaluations. Monitoring Modality Primary Biometrics Tracked Clinical/Regulatory Status Typical Use Profile Oura Ring Gen3 & 4 Heart rate, HRV, breathing disturbances, sleep stages, skin temperature, respiratory rate Wellness tracking; continuous monitoring, not intended for direct diagnosis Continuous 24/7 wear; 5 to 8 days of battery life Apple Watch (Series 9 & newer) Heart rate, ECG, limb movement, sleep apnea notifications FDA-cleared sleep apnea notifications based on breathing disturbances Daily wear; 18 to 48 hours of battery life requiring regular charging ResMed NightOwl Peripheral arterial tone, heart rate, oxygen saturation, accelerometer-based motion FDA-cleared Home Sleep Apnea Test (HSAT) Single-use/short-term diagnostic application; finger-worn sensor with adhesive tape Polysomnography (PSG) EEG, EOG, EMG, ECG, nasal airflow, abdominal/thoracic effort, snoring, body position Gold standard clinical diagnostic method Single-night evaluation conducted in a specialized sleep laboratory Strategic Analysis of the ResMed and Oura Partnership: Bridging Consumer Wearables and Clinical Sleep Medicine The Integrated Referral Pathway and Care Funnel The operationalisation of the partnership commenced with a gradual rollout on April 28th, 2026, followed by the formal public announcement on May 19th, 2026. The integration is currently active for users of the Oura Ring Gen3 and Oura Ring 4 with active Oura memberships within the United States. The mechanism relies on a direct-to-consumer digital referral tunnel. When the Oura application flags a persistent pattern of elevated nighttime breathing disturbances, a dedicated home card is presented to the user. Tapping this card redirects the user to a co-branded, secure digital portal hosted by ResMed. Upon entering the ResMed environment, the user is guided through a comprehensive sleep assessment questionnaire. This assessment is derived from established clinical screening protocols designed to quantify risk factors such as daytime hypersomnolence, loud snoring, and witnessed apneas. To support the subsequent clinical encounter, the portal generates a downloadable, co-branded PDF guide that summarises the user's longitudinal breathing disturbances, sleep efficiency trends and assessment results. This document is structured to bridge the typical communication gap between patient experience and professional medical evaluation, enabling primary care physicians or sleep specialists to rapidly interpret home-recorded sleep metrics. The clinical navigation pathways are supported by ResMed’s digital search tools, including the Sleep Lab Locator and the Dealer Locator, which allow users to locate local sleep diagnostic centers or durable medical equipment (DME) suppliers. Additionally, patients have the option to connect virtually with independent sleep specialists for remote diagnostic evaluation and prescription management. This virtual pathway is designed to lower geographic barriers and expedite the time to therapy, helping to bypass the traditional bottleneck of physical sleep laboratories. Pathway Phase User Action & Biometric Trigger Backend System / Provider Integration Regulatory & Compliance Controls 1. Triage Ring detects frequent breathing disturbances; overnight oxygen drops below 90% Oura App processes biometric data locally; displays co-branded sleep-care card FTC/HIPAA-compliant; no automatic data transfer without explicit user opt-in 2. Assessment User taps app card; completes online screening; downloads discussion guide ResMed host portal runs clinical algorithms; compiles longitudinal trend PDF Structured screening using clinically validated sleep assessment templates 3. Clinical Engagement User matches with telemedicine provider or searches local sleep centers Integration with ResMed Sleep Lab Locator & independent clinical partner platforms State-specific medical licensing compliance; independent clinical decision-making 4. Therapy Initiation Patient undergoes Home Sleep Apnea Test (HSAT); receives CPAP or alternative therapy Integration with DME networks; listings updated via onlinestore.resmed.com FDA-cleared medical diagnostics and therapy prescription compliance Macro Market Synergies: GLP-1 Medications and Comorbidity Management A primary driver for ResMed's consumer-facing strategies is the shifting landscape of obesity management, particularly the widespread adoption of GLP-1 receptor agonists like tirzepatide (Zepbound) and semaglutide. Although initial market assumptions suggested that effective weight loss therapies could diminish the long-term demand for sleep apnea treatments by resolving anatomical airway obstructions, longitudinal market surveillance indicates the opposite effect. Data collected over a two-year surveillance period demonstrates that patients prescribed a GLP-1 medication are 11% more likely to initiate CPAP therapy than those who are not on these weight loss drugs. This acceleration is primarily a funnel effect: the high profile of modern weight loss therapies has drawn historically disengaged populations into primary care settings. When these patients seek medical assistance for weight management, clinicians systematically evaluate their overall health, identifying untreated co-morbidities such as hypertension, type 2 diabetes and obstructive sleep apnea. While weight loss occurs over a prolonged period, treating active sleep apnea is medically urgent due to the immediate risk of stroke or cardiovascular events, leading to high rates of concurrent CPAP prescriptions. Furthermore, ResMed’s tracking of patient compliance indicates that GLP-1 users demonstrate superior long-term adherence. At one year of therapy, GLP-1 patients are 3% more likely to reorder replacement masks from ResMed, and this metric rises to 5% at the two-year mark. This persistent demand is particularly significant given that real-world discontinuation rates for GLP-1 medications typically exceed 50% at one year and continue to climb at two years. As patients discontinue their weight loss medications and potentially regain weight, their reliance on mechanical airway support is reinforced, driving continued utilisation of ResMed's core technologies. This patient flow aligns with ResMed’s broader out-of-hospital care ecosystem, which features cloud-connected therapeutic devices monitored via the myAir and AirView software platforms. These platforms are designed to enhance patient adherence using AI-enabled digital coaching assistants such as Comfort Match, which acts as an automated sleep coach to optimise comfort settings and long-term compliance. Additionally, ResMed’s joint venture with Verily, known as Primasun, and its collaboration with digital platforms like Ognomy Sleep, which offers virtual sleep apnea care and integrates with ResMed’s Pathway program, further support this patient pipeline. Patient Adherence Metric Standard CPAP Cohort Concurrent GLP-1 Cohort Strategic Implication for Supply Chain CPAP Therapy Initiation Rate Baseline +11% higher initiation probability Accelerates equipment deployment and initial diagnostics 1-Year Mask Reorder Rate Baseline +3% higher reorder probability Stabilises high-margin recurring supply revenue 2-Year Mask Reorder Rate Baseline +5% higher reorder probability Offsets typical long-term patient attrition patterns Medication Adherence at 1–2 Years N/A <50% retention (medication discontinued) Reinforces mechanical airway therapy as a permanent baseline Financial Performance and Capital Allocation From a corporate perspective, the partnership is a key component of ResMed’s newly unveiled 2030 Strategy. This plan targets high-single-digit revenue growth and faster earnings growth over the next five years, underpinned by a continuous reinvestment of 7% of revenues into R&D to develop an integrated digital health ecosystem. ResMed has also expanded its manufacturing capabilities, doubling production capacity in major U.S. logistics hubs such as Atlanta and Indianapolis to align with domestic supply chain goals. Financially, ResMed demonstrates strong fundamentals, with a market capitalisation of approximately $29.28 Billion to $29.61 Billion. The company's trailing twelve-month revenues reached $5.3 Billion, characterised by solid gross margins of 62.2% and non-GAAP operating profit margins exceeding 33%. Two-thirds of ResMed’s revenue is generated in the Americas, with the remaining third distributed across Europe, Japan, Australia and other global regions. The company operates with a strong cash flow of $1.8 Billion generated over the trailing twelve months, which supports a balanced capital allocation strategy prioritising research, strategic acquisitions, share buybacks and dividend payments. Despite these strong operational metrics, ResMed’s stock (NYSE: RMD) has recently faced valuation pressures. Trading at approximately $204.15, the shares remain below their 200-day moving average of $251.82 and are down about 30.52% from their 52-week high of $293.81. This compression has driven ResMed's P/E ratio to 19.69, which is very close to its 10-year historical low of 19.47, indicating a favourable valuation for long-term investors. Market analysts also monitor insider activity, which showed approximately $4.9 Million in shares sold by company executives over the preceding three months. Furthermore, ResMed's executive leadership, including Chairman and CEO Mick Farrell and CFO Aaron Bloomer, are scheduled to present at the 46th Annual William Blair Growth Stock Conference on June 2nd, 2026, where they are expected to address market trends, supply chain developments, and long-term growth targets. Market Indicator Current Recorded Value Historical Context / Boundaries Long-Term Strategic Context RMD Share Price $204.15 52-Week Range: $198.61 to $293.80 Trades below the 200-day moving average of $251.82 Trailing P/E Ratio $19.69 10-Year Historical Low: $19.47 Suggests substantial historical undervaluation GF Score™ $95/100 Maximum score potential of $100 Indicates strong profitability (10/10) and growth (10/10) Insider Action $4.9 Million (net sales) Prior 3-month rolling window Warrants investor monitoring regarding executive sentiment Market Value of Oura $11 Billion Standing as the most valuable private wearable firm Underpins strong consumer appeal and brand leverage Strategic Outlook and Regulatory Challenges The partnership between ResMed and Oura reflects a broader transition in sleep medicine from basic tracking toward comprehensive, diagnostic-adjacent monitoring. This transition is driving innovation across multiple device classes, including smart oral appliances developed by firms such as ProSomnus, Dianyx Innovations, and Slow Wave Sleep. These oral appliances, such as the Slow Wave DS8 (marketed as BROSA), have received dual FDA clearance for mild-to-moderate OSA and sleep bruxism, allowing dentists to fit patients with custom 3D-printed devices while patients track physiological responses via consumer devices like the Apple Watch or Oura Ring. The accumulation of continuous biometric data is also shifting clinical focus from raw frequency metrics, such as the Apnea-Hypopnea Index (AHI), toward more predictive risk markers like hypoxic burden and pulse rate variability. The integration of AI-driven diagnostic platforms, such as EnsoSleep PPG, which utilises machine learning to analyse photoplethysmogram signals captured by pulse oximeters, is expected to accelerate home-based diagnosis. Additionally, independent platforms like SleepHQ have emerged, allowing users to integrate sleep data from Apple Health, Oura Ring, and Withings Sleep Tracking Mats with detailed therapy data from cloud-connected CPAP machines. This trend toward open data sharing empowers patients to take a more active role in managing their long-term health, bridging the traditional gap between consumer wellness and clinical care. Regulatory dynamics present another complex layer of consideration. Chief Medical Officer of Oura, Dr. Ricky Bloomfield, has advocated for the development of new, streamlined regulatory pathways for wearable health features.While the FDA has established clearance protocols for specific notification algorithms, such as those utilised by the Apple Watch or Samsung Galaxy Watch, the process remains highly complex for multi-biometric wearables tracking general sleep health. Overcoming these regulatory hurdles will be crucial as companies seek to expand their devices' capabilities from simple risk identification to proactive medical screening, ultimately transforming how the global healthcare system manages chronic sleep and breathing disorders. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Operator Led Evolution in European Healthcare M&A: The Rise of Founder Bankers in HealthTech, MedTech, FemTech and Healthcare AI Executive Summary European healthcare M&A is undergoing a structural transformation that extends well beyond deal volumes and capital flows. The defining shift of the 2025–2026 cycle is not macroeconomic, it is epistemological: the question of who is best qualified to advise on the sale, acquisition and strategic positioning of healthcare technology assets has been fundamentally reopened. For three decades, the architecture of healthcare M&A advisory was dominated by generalist bulge-bracket institutions, Goldman Sachs, J.P. Morgan, Morgan Stanley, Rothschild, whose authority derived from balance-sheet capability, broad institutional relationships and league-table prestige. In 2026, that architecture remains intact for large-cap, cross-border mega-deals exceeding €500 Million. But for the far larger universe of founder-led, venture-backed and growth-stage HealthTech, MedTech, FemTech and Healthcare AI companies, the middle market that generates the majority of European deal volume, a new class of advisor has emerged and, in many sub-sectors, taken primacy. They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​ This report analyses the structural drivers of this advisory evolution, the anatomy of the Founder Banker archetype, the market dynamics reinforcing its ascendancy across HealthTech, MedTech, FemTech and Healthcare AI, and the strategic outlook for founders, investors and acquirers navigating this new landscape. Part I: The Great Rationalisation — Macroeconomic Context for Advisory Evolution From Speculative Exuberance to Industrial Maturity The European HealthTech and MedTech market entered 2026 in a phase termed the "Great Rationalisation", a structural recalibration away from the venture-subsidised experimentation of 2019–2022 toward a disciplined, metrics-driven era of industrial maturity. The decade of cheap capital that enabled a proliferation of fragmented "point solutions", single-feature apps, unvalidated clinical tools and consumer wellness platforms with limited integration into healthcare pathways, is over. The post-pandemic valuation corrections of 2023 acted as a clearing event. Investors who had tolerated "growth at all costs" narratives were confronted with portfolio companies that had burned through capital without achieving clinical validation, reimbursement traction or sustainable unit economics. The result was a decisive shift in the criteria by which healthcare technology assets are valued: away from raw revenue growth toward clinical utility, regulatory resilience, EBITDA generation and integration into existing care pathways. This transition did not reduce market activity, it redirected it. Global healthcare M&A deal value rose 38% to $546.7 Billion in 2025, one of the strongest years since the post-pandemic peak, even as overall deal volumes declined modestly. European healthcare PE deal value reached approximately $80.9 Billion in 2025, up from $59.9 Billion in 2024. The character of this activity changed: fewer transactions completed at higher average values, reflecting a concentration of capital in fewer but larger, high-conviction assets. The Bifurcation Dynamic The most striking feature of the current M&A environment is a bifurcation between volume and value and between asset categories. On one side: premium AI-native platforms, value-based care companies, MDR/IVDR-certified MedTech devices and clinical-grade data systems commanding revenue multiples of 6x–8x and EBITDA multiples of 15x–18x. On the other: undifferentiated SaaS tools, unprofitable point solutions, and consumer wellness apps trading at 2x–4x revenue or entering distressed M&A processes. This bifurcation is the economic logic behind the Founder Banker's ascendancy. When every healthcare technology asset looked like a growth story in 2021, financial engineering was sufficient advisory value. In 2026, when an acquirer must distinguish between a genuinely validated clinical AI platform and a statistically impressive but operationally fragile tool, the intellectual currency is domain fluency and that currency is disproportionately held by advisors who have lived the journey themselves.​​ Private Equity as Volume Engine While strategic M&A attracts the headline transactions, Private Equity (PE) remains the dominant volume driver in European healthcare. European sponsor buyout deal value surged 276% year-to-date in 2025 compared to 2024, reflecting both accumulated dry powder (approximately $2.5 Trillion globally) and increasing pressure to deploy capital from the 2019–2021 vintage. PE portfolios contain a significant backlog of long-held assets requiring exit, making 2026 a year disproportionately shaped by exits rather than new platform formation. The PE consolidation playbook has evolved beyond simple platform buyouts. Add-on acquisitions, secondary buyouts, and continuation funds are the dominant structural mechanisms, as sponsors build pan-European champions across dental, fertility, ophthalmology and veterinary services before eventual strategic exits. Specialist advisors who understand both the operational reality of these roll-up strategies and the buyer psychology of PE exits are in disproportionate demand. Part II: The Anatomy of the Founder Banker, A New Professional Archetype The Founder Banker is defined by a career trajectory that generalist investment banking cannot produce through its traditional analyst-to-managing-director pipeline. These advisors have personally experienced the full lifecycle of company-building: ideation, fundraising, product development, clinical validation, regulatory navigation, commercial scaling and, ultimately, an exit transaction. They carry what is described as "operational empathy", an ability to understand, and critically to credibly communicate, the anxieties, trade-offs and ambitions of a founder navigating their first major liquidity event.​ The comparative profile versus the traditional investment banker is materially different: Feature Traditional Investment Banker Founder Banker Career Path Linear: Analyst → Associate → VP → MD Non-linear: Founder → Exit → Strategic Advisor Core Value Proposition Financial engineering; institutional market access Operational empathy; technical fluency; founder credibility Advisory Philosophy Transactional; prestige-driven; process-oriented Relationship-driven; "Founders for Founders" Diligence Focus Top-line growth; market share; financial ratios Clinical utility; regulatory resilience; unit economics Technical Depth Broad but generalist across sectors Deep vertical specialisation (AI, MDR, NHS procurement) Exit Psychology Process management; information memorandum Empathy with founder motivations; managing valuation resets ​​ The Nelson Advisors Case Study The most visible embodiment of the Founder Banker model in European HealthTech is Nelson Advisors, a London-based boutique founded by Lloyd Price and Paul Hemings, both of whom are former healthcare technology entrepreneurs with successful exits. Lloyd Price brings over 25 years in consumer internet and HealthTech, most notably founding Zesty, a patient engagement platform that navigated complex NHS procurement frameworks before being acquired by Induction Healthcare Group PLC (FTSE:INHC) in 2020. His experience of integrating with hospital legacy systems, navigating clinical pathways, and managing the expectations of a public-company acquirer provides direct operational credibility in advising clients facing analogous exits. Price is also a Health Executive in Residence at UCL's Global Business School for Health and regularly guest lectures at Oxford, Cambridge and IESE Business School Barcelona. Paul Hemings combines senior investment banking experience at Credit Suisse (over $50 Billion in M&A) and Invesco with entrepreneurial experience as co-founder of Neutrally, a metabolic health venture, providing direct founder credibility alongside institutional financial engineering capability. His dual profile, having been both the banker structuring complex cross-border transactions and the founder making the sale decision, is a rare combination that Nelson Advisors explicitly markets as the defining differentiator of their "Founders advising Founders" model. Nelson Advisors team also includes analysts and directors with backgrounds from Rothschild, Citi, Morgan Stanley, ETH Zurich, Johnson & Johnson and Bristol Myers Squibb, reflecting a deliberate strategy of combining traditional investment banking rigour with healthcare operational depth.​ The Broader Ecosystem of Specialist Boutiques Nelson Advisors is the most explicitly "Founder Banker" firm in European HealthTech, but it operates within a broader ecosystem of specialist boutiques that collectively challenge generalist hegemony in the mid-market: Arma Partners — independent advisor to the digital economy with a sophisticated Digital Health and Healthcare AI practice, widely cited for its depth in Health IT and SaaS-in-healthcare​ Clipperton — Paris-headquartered European tech specialist bank with a fast-growing Digital Health and SaaS-in-healthcare franchise, frequently advising venture-backed health platforms on growth capital and strategic exits (e.g. Hublo, DentalMonitoring) ConAlliance — healthcare-only M&A advisor with a strong European MedTech footprint, increasingly active across digital and technology-enabled healthcare assets​ TH Healthcare & Life Sciences — partner-led healthcare M&A advisor working across Europe with private equity and VC-backed digital health and health services technology​ WG Partners — London-based life sciences boutique with over £8.4 billion in completed transactions and an international practice spanning UK, Europe, USA, Asia and Australia Van Lanschot Kempen (formerly Kempen & Co) — premier pan-European specialist investment bank in life sciences and healthcare, with particular strength in biotech and diagnostics​ These firms have collectively taken the primary advisory role for founder-led exits in the €10M–€500M transaction range, the segment that constitutes the majority of European HealthTech deal volume. Part III: Market Dynamics Driving the Founder Banker's Ascendancy, Regulatory Darwinism as Deal Catalyst Perhaps the most powerful structural force driving Founder Banker demand in 2026 is what analysts are calling "Regulatory Darwinism", the use of EU regulatory architecture as a competitive weapon that forces consolidation. The convergence of three regulatory frameworks is creating an unprecedented compliance burden: Regulation Milestone M&A Implication EU AI Act Full enforcement, early 2026 Mandatory "glass box" interpretability; audit-ready AI systems required EU MDR / IVDR Class III deadline, May 2026 MDR certificates become primary financial assets and key valuation levers EUDAMED Mandatory registration, May 2026 Registration prerequisite for exit; competitive intelligence platform The costs of Notified Body certification under MDR/IVDR and the compliance requirements of the EU AI Act are untenable for undercapitalised standalone SMEs, driving them into the arms of larger strategic acquirers who possess the necessary regulatory infrastructure. Acquirers are explicitly purchasing smaller firms to bypass multi-year regulatory bottlenecks and secure immediate market access, a pattern described as "compliance-driven M&A". Advisors who understand the regulatory valuation mechanics, how to price a CE mark, an AI Act audit trail, or an IVDR certificate, command a significant premium over generalists who view compliance as a checkbox rather than a financial asset. The EU AI Act imposes specific obligations on high-risk medical AI systems that materially affect advisory practice: mandatory "glass box" interpretability under Articles 13 and 14 means that investors are rigorously avoiding "black box" AI models in 2026, favouring transparent architectures that satisfy both regulatory requirements and acquirer diligence standards. Founder Bankers, who have typically navigated these frameworks with their own products, are uniquely positioned to translate regulatory exposure into commercial opportunity or risk during transaction processes. The AI Premium in Valuation Healthcare AI has become the single most powerful driver of valuation premiums across European HealthTech. Companies with proprietary algorithms, rigorous clinical validation and deep workflow integration are commanding EV/Revenue multiples of 6x–8x, versus 4x–6x for general HealthTech SaaS. Capital is concentrating around AI-powered diagnostics, ambient clinical intelligence, and research acceleration tools, which jointly captured the majority of AI funding in H1 2025. This "AI premium" is no longer theoretical, it is directly visible in transaction rationales, where strategic acquirers and PE sponsors explicitly target AI-native platforms to modernise legacy portfolios. However, the spread between premium and average assets has widened dramatically, and distinguishing genuine clinical AI from AI-washed marketing requires precisely the technical fluency that Founder Bankers bring. The "Rule of 40", where the sum of a company's revenue growth rate and EBITDA margin must exceed 40%, has become the new benchmark for premium multiples, replacing the growth-at-all-costs metrics of earlier cycles. In Q4 2025, each 10-point improvement in a company's Rule of 40 score was associated with approximately a 1.1x increase in EV/Revenue multiple.​ The Series B+ Capital Gap and Transatlantic Flows A defining feature of the 2025–2026 period is the intensity of transatlantic capital flows into European HealthTech. US corporate and growth funds participated in 62% of late-stage European deals in 2025, a triple increase from 2023 levels. This activity is helping bridge the historical "Series B+ Gap" that has constrained European founders' ability to raise large late-stage rounds domestically.​ Notable transactions illustrate the trend: the $900 Million Series E for Finnish health-tech company Ōura and the $600 Million strategic round for UK-based Isomorphic Labs demonstrate that US capital is actively targeting European innovators who have already navigated the stringent EU regulatory environment, viewing them as "de-risked" assets ready for global deployment. Europe's digital health funding jumped 82% year-on-year to $2.0 Billion in Q1 2025, its second-highest quarterly total on record. For advisors, transatlantic cross-border work requires a dual fluency: understanding how US acquirers (from Alphabet to UnitedHealth to Philips) evaluate European assets, what regulatory questions they ask, how NHS or European public payer relationships translate into US strategic value, and how valuation gaps between US and European markets can be bridged. Founder Bankers who have managed cross-border scaling journeys are naturally positioned to navigate this translation. Part IV: Sub-Sector Dynamics, HealthTech and Digital Health European digital health funding increased by 52% year-on-year in H1 2025, reaching $3.4 Billion across 182 deals. The overall HealthTech M&A deal volume in H1 2025 reached 277 deals, projecting a full-year total well above the 467 deals recorded in 2024, with disclosed deal value reaching $10.3 Billion in H1 2025 and on pace to surpass the 2024 total of $19.2 Billion.​ The most valued sub-segments are AI-driven clinical decision support, EHR integration platforms and value-based care infrastructure. The shift away from B2C consumer health toward B2B enterprise and NHS/EU health system deployments has been decisive, acquirers reward assets with demonstrable ROI for payers, not consumer engagement metrics. Vendor sprawl fatigue among hospital CIOs is driving demand for integrated platforms over point solutions, creating a market structure that rewards consolidation advisors. MedTech Global MedTech deal value surged to $97.6 billion in 2025 — the highest level in over a decade, driven by three mega-deals, though overall deal count remained below historical norms at 46 announced deals through November. The European MedTech landscape is defined by surgical robotics maturation, AI-driven medical imaging, and the compliance-driven consolidation wave triggered by MDR/IVDR. Surgical robotics has transitioned from experimental to challenger platforms seeking global expansion. Companies including CMR Surgical (Versius, $1Bn+ total funding), Noah Medical (Galaxy Lung System, $400M) and Distalmotion (Dexter Hybrid, $300M) represent European innovators in active pursuit of strategic partnerships and acquisition processes. Medical imaging and diagnostics saw venture investment reach $19.1 Billion in 2024, with acquirers focusing on AI tools that automate patient episode management from intake through treatment.​ The advisory challenge in MedTech is distinct from Software: technical diligence on hardware, clinical evidence packages, Notified Body relationships and post-market surveillance data require advisors who can speak the language of regulatory bodies, clinicians and financial buyers simultaneously, a rare combination that favours specialists over generalists. FemTech By early 2026, FemTech had evolved from a niche sub-sector into a major pillar of global healthcare acquisition strategy. The European FemTech market reached €2.4 Billion in 2024 and is projected to nearly quadruple to €9.7 Billion by 2033, growing at approximately 16% CAGR. The sector has attracted over £480 Million in investment funding in the UK alone, growing at 30%. The McKinsey 2024 report estimated that improving women's health outcomes could add £1 Trillion to the global economy by 2040, a macro-economic argument that has catalysed strategic acquirer interest from pharmaceutical groups, health systems and consumer health conglomerates. The 2025 BCG X survey highlighted that only 41% of women believed sufficient health services existed for their concerns, a TAM signal that strategic buyers find compelling. M&A dynamics in FemTech mirror the broader sector shift: fertility platforms (IVI, FutureLife) have established consolidation playbooks through PE-backed roll-ups of regional clinic networks. FutureLife's 2024 acquisition of Bristol-based BCRM expanded its UK regional presence beyond London in a landmark deal. Phoenix PE invested in London Gynaecology in 2024, targeting scaling of private gynaecology care against long NHS waiting times. Flo Health's unicorn valuation in 2024 as the first women's health unicorn established benchmark valuations for digital FemTech platforms.​ The advisory opportunity in FemTech is compounded by the historically low analyst coverage: most generalist investment banks lack dedicated FemTech practices, creating a significant gap that specialist advisors fill. Founder Bankers with direct experience in women's health, consumer health or adjacent clinical areas carry immediate credibility with both founders (who often have personal motivations for building in the space) and acquirers (who need to understand clinical outcome differentiation). Healthcare AI Healthcare AI has emerged as the fastest-growing and most contested sub-sector in European HealthTech M&A. The top-funded sub-sectors in European HealthTech H1 2025 were drug discovery (including TechBio using AI/bioinformatics), medical diagnostics (AI-driven radiology and pathology) and digital health platforms with embedded AI. Three acquisition playbooks are consolidating the Healthcare AI landscape:​ Platform Acquisitions — Corporate buyers acquiring AI-rich assets to embed decision support across care pathways and accelerate digital transformation AI-Native Roll-Ups — PE-backed mergers of traditional healthcare software businesses with AI start-ups, creating scaled platforms with differentiated data and automation Regulatory Arbitrage Consolidation — EU MDR/IVDR, EU AI Act and EHDS raising the compliance bar, pushing sub-scale SMEs into better-capitalised consolidators The advisory challenge in Healthcare AI is the most technically demanding in the sector: distinguishing between genuinely clinical AI (with validated algorithms, real-world evidence, EHR integration and a regulatory pathway) and AI-adjacent marketing requires deep technical diligence that generalist advisors are often poorly equipped to perform. Founder Bankers who have built or operated clinical AI products understand the difference between a demo and a deployed system, and can translate that distinction into valuation arguments that hold up under buyer scrutiny.​ Part V: The Advisory Market Landscape, Specialists vs. Generalists, The League Table Reconfigured The advisory market for European healthcare M&A is best understood as segmented by deal size and asset complexity, rather than simply by advisory prestige: Advisor Primary Strength Deal Size Sweet Spot Key Sub-sectors Goldman Sachs Large-cap exits, IPOs ($97.5bn+ value, 2024) €500M+ Mega-deals, public M&A Rothschild & Co Mid-market ubiquity, PE relationships (132 deals, 2024) €100M–€2bn Broad mid-market healthcare J.P. Morgan Complex cross-border strategic M&A €500M+ Large-cap pharma, MedTech Morgan Stanley Financial sponsor relationships €200M+ PE-backed platforms Arma Partners Digital Health, SaaS, Healthcare IT €20M–€500M Digital health, tech-enabled care Nelson Advisors Founder-led exits, Healthcare AI €25M–€200M HealthTech, MedTech, AI, FemTech Clipperton High-growth Tech/SaaS-in-healthcare €10M–€300M Digital health, SaaS platforms Van Lanschot Kempen Biotech, Diagnostics, Life Sciences €50M–€500M MedTech, biotech, diagnostics The critical insight from this segmentation is that the competitive gap is not between bulge-bracket and boutique in terms of capability, it is between generic and specialised in terms of relevance to the asset. For a founder-led healthcare AI company with €15M ARR seeking a strategic exit, Goldman Sachs is not the natural advisor: they will not have a dedicated partner who understands AI Act compliance implications for valuation, can credibly articulate clinical validation to a NHS procurement-aware buyer, or empathise with the psychological complexity of a founder's first liquidity event. Even generalist mega-firms have acknowledged this dynamic. Goldman Sachs has been cited as hiring medical doctors to lead its EMEA healthcare teams, recognising that bio-technical diligence in Healthcare AI requires clinical depth, not purely financial acuity. This is itself evidence of the structural shift the Founder Banker embodies.​ The Consolidation of Advisory Firms The boutique advisory ecosystem is itself undergoing consolidation. Stifel's acquisition of Bryan Garnier and Houlihan Lokey's European healthcare expansion signal a maturing mid-market where successful specialist advisory firms are becoming acquisition targets for larger institutions seeking domain expertise. This dynamic validates the model: the value being created by specialist boutiques is real enough that larger platforms are acquiring it rather than building it organically.​ Part VI: Due Diligence Evolution, The Founder Banker's Operational Contribution, Beyond the Information Memorandum The Founder Banker's value is most tangible in the diligence and process phases of a transaction. Modern healthcare technology M&A diligence in 2026 extends far beyond financial review into technical architecture audits, regulatory compliance assessments, clinical evidence evaluation and integration planning, each requiring expertise that traditional investment bankers lack.​ Key diligence areas where Founder Bankers provide differential value: Diligence Focus 2026 Requirement Where Founder Bankers Add Value Model Architecture GPAI compliance; AI Act transparency obligations Distinguishing genuinely interpretable AI from marketing claims Data Provenance Audit of training datasets; IP provenance Understanding real-world data collection practices vs. theoretical claims Clinical Validation Real-world evidence; RCT vs. retrospective data Assessing clinical evidence quality and reimbursement implications Regulatory Status MDR certificates; AI Act audit readiness Translating regulatory certificates into valuation premiums Integration Reality EHR/legacy stack compatibility; CIO skepticism Managing acquirer expectations based on first-hand integration experience AI-Augmented Advisory Ironically, Healthcare AI is also reshaping the advisory process itself. AI-driven due diligence tools are enabling faster deal evaluations and superior risk detection through automated document review and machine learning-powered pattern recognition. Automated lease analysis has become 70% faster and error rates in compliance checks have dropped by 40% through AI-powered tools, changing the economics and speed of deal execution. Founder Bankers who embrace these tools can maintain quality while significantly improving deal velocity, a competitive advantage in auction processes where speed of diligence often determines mandate retention.​ Part VII: Strategic Recommendations and Outlook, For Founders Preparing for Exit The advisory selection decision is now strategic, not simply administrative. The choice between a generalist firm and a Founder Banker boutique should be driven by asset complexity, buyer universe, and the specific technical or regulatory narrative that needs to be constructed and defended. Prioritise clinical utility narrative: In 2026, value is determined by integration into clinical pathways and measurable ROI for health systems, advisors must be able to construct and defend this narrative with technical credibility Treat regulatory assets as financial assets: MDR certificates, AI Act compliance documentation and EUDAMED registration are valuation levers, not administrative formalities, advisors who understand this translate compliance investment into premium multiples Align with Rule of 40 benchmarking: The primary financial metric for commanding premium multiple is the Rule of 40, advisors should help prepare companies to present against this benchmark, including clarity on path to profitability Leverage transatlantic buyer intelligence: US acquirers participated in 62% of late-stage European deals in 2025; advisors with direct US relationships and cross-border execution experience are essential for competitive processes​ For Strategic Acquirers and PE Sponsors The Founder Banker model also changes how buyers should structure their advisory relationships. Buy-side M&A in HealthTech increasingly requires advisors who can assess operational reality, not just financial metrics, to avoid overpaying for technically impressive but commercially fragile assets. The three dominant acquisition playbooks for 2026, platform consolidation, AI-native roll-ups, and regulatory arbitrage, each require a different type of advisor expertise that the generalist advisory model struggles to provide at the sub-€500M tier. Market Outlook: 2026–2027 The European HealthTech market is valued at approximately $96.68 Billion in 2025 and projected to reach $222.22 Billion by 2030. Against this backdrop, several trends are likely to define the advisory landscape over the next 18–24 months:​ Continued bifurcation: The gap between premium AI-validated assets and undifferentiated point solutions will widen further, increasing the valuation sensitivity to advisory quality Distressed M&A expansion: The convergence of MDR/IVDR enforcement, EU AI Act obligations and PE exit pressure will accelerate distressed M&A as undercapitalised firms are forced to sell​ FemTech institutionalisation: As FemTech matures from niche to mainstream acquisition target, demand for advisors with specific women's health expertise will intensify Healthcare AI commoditisation risk: As more companies claim AI capabilities, the premium for genuine clinical AI will concentrate in a smaller number of genuinely differentiated assets, creating advisory mandate opportunities for specialists who can credibly separate signal from noise Founder Banker model replication: The success of the pioneer Founder Banker model will attract imitation; the differentiation will increasingly shift to quality of exits, sector depth, and specific sub-sector specialisation (e.g., FemTech vs. surgical robotics vs. clinical AI) rather than the generic "founder background" credential alone Conclusion The emergence of the Founder Banker in European healthcare M&A is not a cyclical phenomenon or a niche trend, it is a structural recalibration of the advisory market to match the irreducible complexity of 2026's healthcare technology assets. When regulatory compliance determines enterprise value, when clinical validation is the primary M&A diligence question, and when the psychological complexity of founder exits requires advisors who have navigated them personally, the traditional linear career path of the investment banker is an insufficient preparation for the advisory role. The Great Rationalisation has made this mismatch visible. The firms and individuals who built their advisory practices on operational pedigree, Nelson Advisors, Arma Partners, Clipperton, ConAlliance, have found themselves structurally advantaged in precisely the market environment that 2026 has produced. The measure of this model's success will be its proof through exits: not the size of deals in the press release, but the quality of outcomes for founders, investors and health systems that trusted them with the most consequential decisions of their professional lives. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

10 Key Lessons in 'the Shift from CoPilots to Agents in Healthcare' The Shift from Copilots to Agents in Healthcare: Ten Key Lessons for Systemic Transformation The healthcare sector is undergoing a profound structural evolution as artificial intelligence (AI) transitions from an assistive, reactive tool into an autonomous execution layer. According to financial assessments, global AI expenditure is projected to rise from $1.76 Trillion in 2025 to $2.52 Trillion in 2026, before reaching $3.34 Trillion in 2027. A significant concentration of venture capital is driving this transformation; AI firms raised approximately $242 Billion in Q1 2026, accounting for around 80% of global venture funding during that quarter. Furthermore, a Silicon Valley Bank analysis revealed that for every venture capital dollar invested in crypto-related companies in 2025, 40 cents was directed to organisations simultaneously building AI products. Within healthcare systems, this macro capital allocation is accelerating a shift from conversational "copilots", which require constant human guidance, to "agents" capable of autonomous, goal-driven workflow execution. The contemporary healthcare AI architecture progresses from a standardised data foundation to a unified control plane, branching into distinct assistive and autonomous execution modules. At CAHOTECH, Keshri Kr. Asthana, Chief Technology Officer of Microsoft India's Public Sector, outlined this conceptual progression, illustrating how health systems must transition from traditional data storage toward proactive systems capable of independent execution. Architectural Attribute Deterministic Bots Reactive Copilots Autonomous AI Agents Operational Logic Predefined rules and decision trees. Machine learning models responding directly to prompts. Goal-directed, multi-step execution loops. State Management Stateless; each execution is processed independently. Short-term context maintained within an active session. Persistent memory modules and database logs. Integration Method Isolated application interfaces, such as web chat. Embedded assistance within existing office applications. System-wide integration via secure APIs and webhooks. Control Model Human-in-the-loop required for every direct interaction. Humans review, approve, and execute each step. Automated validation, exception handling, and guardrails. Clinical Use Case Basic appointment booking and symptom FAQ routing. Ambient clinical note summaries and history compilation. Prior authorisation, clinical triage, and care coordination. Understanding this structural blueprint is essential as organisations navigate the operational and clinical shifts detailed in the following ten lessons. Lesson 1: Transitioning from Reactive Task-Specific Assistance to Proactive Systems of Action The primary evolution of enterprise AI involves moving beyond "Democratisation 1.0", which focused on giving employees access to assistive tools, toward "Democratisation 2.0," which emphasises the architecture of autonomous action. Traditional copilots operate on a reactive basis, waiting for a human operator to provide an input before generating an output. In contrast, autonomous agents establish their own sub-goals, evaluate variable context and execute complex workflows across multiple systems with minimal human intervention. This marks the emergence of the "System of Action" as a critical software layer. Historically, enterprises relied on systems of record to store information and systems of engagement to facilitate interaction; the system of action assumes responsibility for execution, turning software into the default operator. Operational metrics underscore the urgency of this transition. Gartner research highlights that the share of organisations investing in new technology for business and IT transformation jumped from 15% in 2024 to 52% in 2025, with all surveyed organisations planning to deploy agentic AI by 2028. This momentum is reflected in active environments: in single day analyses of advanced conversational platforms, 45.7% of daily interactions were system triggered rather than user-initiated, demonstrating that a substantial share of operations is already handled by persistent agents running in the background. Lesson 2: Shifting the Development Paradigm from Deterministic Programming to Probabilistic Agent Evaluation The transition to agentic systems fundamentally alters how healthcare software is constructed. Traditional clinical systems are built on deterministic programming paradigms, where developers write code, assemble features, and run structured test suites to guarantee highly predictable, rule-bound behaviours. Conversely, agentic AI operates within a probabilistic model. This new paradigm requires a shift from writing static code to configuring bounded systems, designing natural language instructions and establishing real-time evaluation loops. As defined in modern healthcare stack frameworks, an agent is a logical composition of a large language model (LLM), instructions, and specific tools. The operational cycle of the agentic software layer relies on continuous feedback loops across four distinct phases: perception, cognitive processing and planning, action execution and active learning. Consequently, developers must pivot from micro-managing individual execution steps to orchestrating how systems analyse context, make decisions, and interact with external applications. Lesson 3: Overcoming Data Fragmentation and Legacy Silos through Agentic Orchestration A primary barrier to healthcare efficiency is the fragmentation of data across payers, providers, and legacy systems.Clinical records, claims data, eligibility parameters, and social determinants of health routinely exist in isolated databases that fail to communicate. Rather than forcing organisations to undergo costly legacy replacements, autonomous agents function as intelligent translation layers, pulling data from multiple sources into a unified interface and orchestrating workflows in real time. An illustration of this capability is the integration of multi-agent orchestration frameworks like Amazon Bedrock AgentCore with standardized healthcare data repositories. This architecture utilises AWS HealthLake to securely store structured, FHIR-compliant clinical data while using Amazon S3 for unstructured medical documents like radiology reports or handwritten notes. When a provider orders a procedure, an orchestrator agent can automatically detect the request, extract relevant clinical indicators across these distinct storage layers, and compile a complete prior authorisation packet in under ten minutes. This interoperability is further enhanced by open standards such as the Model Context Protocol (MCP). For example, the SAS Viya MCP Server exposes advanced clinical analytical models directly to agents built on various LLM interfaces (such as Claude). This allows agents to execute domain aware clinical tasks and explore real-time data cohorts without duplicating business logic or bypassing established enterprise security policies. Lesson 4: Re-Architecting Security and Risk Frameworks for Privileged Agent Identities As healthcare organisations transition to autonomous systems, traditional static security controls become obsolete. Agents act as privileged digital identities with direct access to database records, application interfaces and other agent systems.This high-velocity interaction requires security to be embedded natively into the AI agent stack itself. To mitigate these risks, organisations are adopting Secure-by-Design AI blueprints, such as the collaborative architecture developed by CrowdStrike and NVIDIA, which delivers continuous runtime enforcement and visibility across high-performance compute environments. Furthermore, operating agents in production requires managing "agent-native" infrastructure challenges. As fleet management platforms like Keycard enter enterprise production, they must handle thundering herd patterns, collapse latency variances and manage secure tool-calling protocols. To address these challenges, developers utilise specialised frameworks like the eight-goal C.O.P.I.L.O.T.S. framework, designed to govern agents once they transition from experimental demos into active operational environments. Lesson 5: Transitioning from Simple Retrieval-Augmented Generation to Advanced Knowledge Engineering Early generative AI implementations relied heavily on Retrieval-Augmented Generation (RAG) to provide context to models. However, as agentic workflows mature, simple retrieval tuning is proving insufficient for complex clinical decision-making. While RAG is equivalent to "bringing books to the exam," advanced Knowledge Engineering "teaches the agent how to study," emphasising memory architecture over simple search matching. To establish durable competitive advantages in the agentic economy, technology companies must build defensive moats based on workflow ownership and execution depth rather than superficial chat features. This defensibility is established through deep integration into critical clinical pathways, generating high switching costs. Furthermore, as these agents execute repetitive administrative and clinical tasks, they generate proprietary execution data that continuously refines their decision models, creating a compounding advantage. This model relies on specialised, highly efficient language models and value-based pricing aligned with clinical outcomes, rather than traditional, seat-based software licensing. 10 Key Lessons in 'the Shift from CoPilots to Agents in Healthcare' Lesson 6: Managing the Transition from Execution Velocity to Compressed Decision Latency The introduction of copilots drastically increases execution speed; however, if the surrounding decision-making model remains unchanged, severe operational friction emerges. In a copilot environment, humans still review, prioritise and approve actions at a manual, fixed cadence, resulting in a system bottleneck defined by "decision latency". Agents resolve this by compressing execution into continuous, automated flows. Operational Metric Manual / Copilot Workflow Agent-Led Workflow Submission Processing Time Several business days of manual collection and form entry. Under 10 minutes via automated multi-agent orchestration. System Validation Gates Scheduled approvals and deferred manual compliance checks. Continuous machine-consumable validation signals. User Interaction Hold Times Average of 11 minutes in patient-facing queues. Reduced to 1 minute, with a 24/7 active response rate. Clinical Terminology Migration Multiple days of manual verification and mapping. Completed in a few hours with a supervisor agent. At CAHOCON 2026, Ms. Soujanya Narala delivered a presentation titled "From Dependency to Enforcement: Designing Systems That Ensure Action," emphasising that successful transition requires moving decisions earlier into the system itself. Instead of deferring validation, organisations must build continuous control planes where compliance, safety, and operational constraints are encoded directly into the software pipelines. Human oversight then shifts from manually executing every step to defining high-level intent, managing complex exceptions, and refining system boundaries. Lesson 7: Mitigating Downstream Error Propagation via Constellation Architectures and Supervisor Loops In previous generative models, isolated errors (such as a flawed document summary) were easily identified and corrected by the human operator. However, because agents operate across multi-step, autonomous workflows, an incorrect decision made early in a cycle can propagate and compound downstream before a human has the opportunity to intervene.Healthcare systems require specialised architectures to isolate and mitigate these failures. One approach involves a supervisor-led agentic architecture. For example, at IMO Health, clinical terminology migration is managed by a Supervisor Agent that coordinates specialised sub-agents, including Term Inspection, Term Suggestion, and Revalidation Agents. The supervisor operates in a persistent cognitive loop: it interprets the clinical request, invokes the appropriate specialised tool, evaluates the output, and decides the next action, reducing a multi-day migration process to a few hours with 73% accuracy. For high-stakes, patient-facing voice interactions, organisations utilise advanced clinical constellation architectures.Hippocratic AI’s Polaris 3.0 and Polaris 5.0 systems deploy 22 specialised LLMs (ranging from 4.2 to 5 trillion parameters in total) that coordinate to manage safety. This constellation includes dedicated clinical models that triple-check lab values, verify drug contraindications with 99.95% accuracy, classify urgent symptoms across seven distinct body systems, and maintain natural multilingual conversations mid-call without context loss. Lesson 8: Earning Clinical Trust through Bounded Autonomy and the "Zero-Loss" Principle In healthcare, high performance alone is insufficient; powerful AI operating without strict clinical guardrails represents a severe operational liability, giving rise to the demand for "Zero-Loss AI Agents". Automated systems do not automatically translate to improved experiences, and poorly implemented interfaces risk eroding provider trust through opaque decision-making logic. At the MVA R&D Network seminar, industry experts emphasised that deploying agentic systems in highly regulated environments requires a workflow-first mindset, clearly defined boundaries, and strict accountability. Sonja Aits of Lund University highlighted the necessity of robust coordination frameworks and human-in-the-loop designs to ensure clinical transparency, while Søren Thorup of Adalyon urged organisations to "kill the proofs-of-concept (PoCs)" and design agentic AI directly for production with built-in auditability and bounded autonomy. Dr. Vandita Gupta's CAHOCON presentation, "What CEOs Want from MedTech: Proof, Performance and Predictability," reinforces that clinical and executive buy-in is earned through transparent, evidence-based performance rather than speculative claims. Lesson 9: Launching in Back-Office Revenue Cycle Management to Establish Safe Sandboxes for Validation To safely manage the risks associated with autonomous systems, healthcare organizations should prioritize deployment within back-office administrative functions. Back-office operations, including accounts receivable follow-up, denials management, underpayment tracking and clinical coding, are heavily governed by standardised, structured rules. This administrative sandbox provides a low-risk environment to test, validate and refine agent behaviours before scaling them into patient-facing clinical workflows. Healthcare Technology Platform Core Functionality Real-World Performance & Scope Ascertain Automates prior authorisations, eligibility checks, and referral workflows. Achieved a 95% faster post-acute submission rate and cut manual click volumes by 80%. AKASA Revenue cycle management automation, including inpatient encounter coding. Deploys Coding Optimiser and CDI Optimiser to identify documentation gaps. Suki Voice-activated clinical assistant and EHR integration platform. Partners with HealthEdge to bring ambient intelligence to health plan care managers. Corti Speech-to-text, medical coding, and prior authorisation documentation. Automatically extracts clinical context to generate evidence-based letters. McKinsey analysis indicates that utilising agentic AI to enable the revenue cycle can cut the cost to collect by 30% to 60%, accelerating cash realisation while freeing administrative staff to manage complex exceptions. In 2025, over 30% of healthcare providers prioritised the deployment of AI across seven specific revenue cycle use cases, illustrating the industry-wide focus on capturing back-office efficiencies. Lesson 10: Managing Organisational Inertia and Navigating the Performance Plateau Transitioning from copilots to agents is not merely a tooling upgrade; it is a fundamental restructuring of how control and labour are distributed across the enterprise. Large-scale case studies of agentic transitions demonstrate that replacing copilots with autonomous agents capable of handling 90% to 95% of operational workflows requires a willingness to "go flat" for a year, tolerating temporary performance plateaus during core system reconstruction, before achieving dramatic operational scaling on the other side of the transition. To navigate this organisational shift, leaders must actively bridge the gap between technical developers and clinical practitioners. Dr. Arun V Joy's CAHOCON presentation, "Stethoscopes to Smartphones - Bridging the Clinician-Tech Gap," highlights that managing workforce adoption is as critical as the underlying software architecture. Successful deployment depends on aligning clinical end-users with the continuous control plane, ensuring that clinical staff trust the autonomous actions executed by background agents. Strategic Recommendations for the Agentic Transition For clinical and technology executives preparing to transition from copilots to autonomous agents, the following structural roadmap is recommended: First, organisations should adopt the four-stage implementation framework: Identify, Align, Evaluate, Deliver. Leadership must identify the highest-volume, most error-prone administrative processes, specifically targeting back-office revenue cycle functions such as denials management or coding validation. The proposed agentic solution must then be aligned with existing clinical governance structures and payer policies. Second, engineering teams must evaluate existing data assets and clean fragmented data sources. This requires setting up robust, secure API integrations through modern middleware standards like the Model Context Protocol to ensure the agents have real-time, governed access to both structured clinical repositories and unstructured document storage. Third, organisations must design a continuous control plane that enforces "Secure-by-Design" principles. This involves implementing Constitutional AI with hard-coded, non-overridable rules for data sovereignty, continuous immutable audit logging and automated human-in-the-loop triggers for high-stakes clinical or financial exceptions. By prioritising bounded autonomy and supervisor-led validation loops, healthcare organisations can safely transition from human-dependent tools to scalable, trustworthy digital co-workers. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Metrics for a HealthTech and MedTech company to raise a Series A round in Europe in today's environment Key Metrics and Strategic Determinants for Series A Capital Raising in the 2025-2026 Environment The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a rigorous demonstration of clinical utility, regulatory fortitude and a clear line of sight to measurable return on investment (ROI) within strained healthcare systems. This structural transformation is driven by elevated costs of capital and the simultaneous enforcement of complex legislative frameworks, including the EU Medical Device Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), and the EU AI Act. For a startup to secure Series A capital today, it must navigate a landscape where capital is highly polarised, concentrating in a narrow cohort of "de-risked" assets that can prove their integration into clinical pathways and their ability to alleviate systemic burdens. The Macroeconomic Landscape and Venture Capital Dynamics The European healthtech market, valued at approximately $96.68 Billion in 2025, is projected to reach over $222 Billion by 2030, representing a compound annual growth rate (CAGR) of 18.11%. Despite this robust outlook, the venture capital environment is marked by a "cautious yet discernible rebound". While global digital health funding rose to $28.8 Billion in 2025, a 9% increase year over year, the number of deals fell to a five-year low. This divergence signifies a move toward "bigger cheques and fewer bets," where capital flows to companies with clear clinical, technological, or commercial validation. Europe has emerged as the fastest-growing region globally for digital health, with funding surging by 52% in the first half of 2025 compared to the same period in 2024. This resilience is supported by a surge in U.S. investor participation, which accounted for 62% of participants in late-stage European deals by 2025, a threefold increase from 2023. For a Series A founder, this globalised investor base provides access to deeper capital pools but also imposes more stringent US style due diligence requirements focused on commercial scalability and reimbursement visibility. European Healthcare Funding and Transaction Benchmarks (2024-2026) Metric 2024 Actual 2025 Estimated 2026 Projected Global Healthcare M&A Volume $417.8 Bn $450 Bn $3.9 Trn(Global all sectors) European Healthcare PE Value $59.9 Bn $80.9 Bn $95 Bn MedTech Deal Count (Europe) 41 42 50+ Average MedTech Deal Size $1.6 Bn $795.1M (Adj.) $900M Median Series A Valuation $37.4M $31.0M TBD Series B Capital Trend 84% vs 2021 Persistent bottleneck Tentative recovery Average Series A Round Size $10.2M $12.9M $15M The "Series B bottleneck" remains a critical factor for Series A founders to consider. With the time between Seed and Series A rounds extending to an average of 774 days, startups must manage their cash mechanics with extreme precision. Investors now scrutinize the "bridge round frequency," which sits at approximately 37% of deals, as a signal of a company's inability to reach meaningful inflection points on its original runway. Consequently, a Series A pitch must clearly articulate how the fresh capital will carry the company not just to its next round, but through to a "Series A Off-Ramp", an exit to private equity or a strategic acquirer if the venture path narrows. Financial Benchmarks and Valuation Multiples Valuations in 2026 are heavily dependent on sub-sector alignment and profitability profiles. The market has moved beyond the "growth at all costs" paradigm of the zero interest rate policy era, where valuations were often detached from unit economics. In the current environment, revenue multiples are compressed for companies with high burn rates, while those demonstrating the "Rule of 40", where the sum of the growth rate and free cash flow margin equals or exceeds 40%, command significant premiums Sub-Sector Valuation Multiples (January 2026 Outlook) Sub-sector EV / Revenue Multiple EV / EBITDA Multiple Strategic Rationale Premium AI & Data Platforms 6.0 - 8.0 15 - 18 Proprietary algorithms; Rule of 40 performance. Value-Based Care (VBC) 5.5 - 7.0 12 - 1 Demonstrable ROI for payers; population health impact. AI-First Drug Discovery 8.0 - 15.0 N/A High-risk, high-reward; biopharma capability multiplier. General HealthTech SaaS 4.0 - 6.0 10 - 13 Stable retention; predictable unit economics. MedTech Hardware (MDR-ready) 3.5 - 5.5 11 - 14 Regulated moats; high barriers to entry. Consumer Health & Wellness 2.0 - 4.0 8 - 11 Sensitive to discretionary spending; higher churn. Unprofitable / Early Stage 3.0 - 4.0 N/A Candidates for distressed M&A or consolidation. A defining metric for AI-native healthcare companies in 2026 is the Annual Recurring Revenue (ARR) per Full-Time Employee (FTE). Traditional healthcare services typically generate between $100,000 and $200,000 in ARR per FTE, while healthcare SaaS platforms pre-AI reached $200,000 to $400,000. In contrast, AI native platforms are now achieving ARR per FTE metrics between $500,000 and over $1Million, driven by the automation of administrative workflows and clinical documentation. This productivity leap allows these companies to achieve software-like margins even as they scale services, a factor that investors view as a "gold standard" for Series A investment. Regulatory Fortitude as a Series A Prerequisite The implementation of the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) has fundamentally altered the competitive landscape, creating what industry analysts call "Regulatory Darwinism". These regulations have established a capital intensive barrier to entry that is often untenable for standalone small and medium sized enterprises (SMEs) lacking significant balance sheet depth. Consequently, the venture capital thesis has shifted from funding regulatory risk to backing companies that have already built "regulatory moats". For a Series A startup, regulatory planning must be integrated into the technical roadmap from day one. Investors now expect to see a clear EMA or FDA pathway, early risk classifications, and documented compliance with software safety standards such as IEC 62304. The regulatory phase in 2026 has shifted from rule making to enforcement, and companies that cannot provide a definitive timeline for Notified Body certification or conformity assessments see their strategic options narrow rapidly. Key Regulatory Milestones and Timelines (2025-2026) Regulation / System Key Milestone Date Implication for Startups EUDAMED Mandatory application (Modules 1, 2, 3, 5) May 28, 2026 Required for all economic operators; mandatory SRN. EU AI Act Full enforcement for "High-Risk" systems August 2, 2026 Stringent data governance and human oversight required. EHDS Full secondary use provisions roll-out Gradual to 2029 Unlocks patient data for R&D and AI training. Biotech Act Framework aimed at biomanufacturing Expected Q4 2026 Streamlined clinical trial procedures. IVDR Mandatory compliance for legacy IVDs May 27, 2026 High risk of supply interruption for non-compliant firms. The EU AI Act, in particular, has introduced a "binary filter" for healthtech investment. Medical AI tools categorized as high-risk must meet rigorous requirements for data governance, human oversight, and transparency. This has rendered "Black Box" AI models effectively un-investable in the clinical context. Investors are instead redirecting capital toward "Glass Box" or explainable AI architectures and companies that have built their technology stacks with privacy by design principles. Clinical Evidence and the EHDS Era In 2026, evidence has stopped being a differentiator and has become the "price of admission". Investors prioritise "more mature companies" that can provide clinical proof points, reimbursement visibility and a clear role within therapeutic strategies. The European Health Data Space (EHDS) is the single most significant structural driver for healthtech investment in this period. By mandating that data holders, such as hospitals and clinics, make electronic health data available for secondary use, the EU has effectively created a new asset class: curated clinical data. Startups that provide the "picks and shovels" for this data economy, such as interoperability layers, data cleaning tools, and de-identification platforms are commanding premium valuations. Clinical validation now requires moving beyond isolated pilots to demonstrating impact in real-world care settings. Procurement criteria in 2026 increasingly demand outcome measures mapped to local environments rather than controlled demo conditions, as health systems reject "isolated innovations" that fail to change broader economics. Clinical and Technical Due Diligence Focus Areas (2026) Diligence Focus Series A Requirement Strategic Rationale Model Architecture Mandatory transparency; explainability. Satisfy EU AI Act; avoid "Black Box" risk. Data Provenance Audit of training datasets; IP provenance. Mitigate legal risk; ensure data quality. Interoperability Fast FHIR endpoints; clean DICOM support. Reduce friction for hospital CIOs; enable scaling. Clinical Strategy Defensible claims; path to HTA. Secure reimbursement; satisfy investor scrutiny. Cybersecurity SBOM-ready releases; threat modeling. Meet NIS2/MDR expectations; build trust. The transition from "speculative science to practical infrastructure" is evident in the funding clusters of 2025. Health Management Solutions, which focuses on workflow and reimbursement ready tools, overtook research focused TechBio as the top funded cluster, attracting$5.45 Billion. For a Series A company, this means that the "clinical story" must be paired with a "workflow story" that proves the solution reduces total hospital days or optimises resource use. Market Access and Reimbursement Pathways Reimbursement is the ultimate validator for a European healthtech startup. Without a clear path to being paid by national or regional health insurers, a company is viewed as a high-risk gamble. Germany and France continue to lead the way with structured pathways, but both have introduced new requirements in 2026 that founders must address. The Evolution of the German DiGA Pathway Germany's DiGA (Digitale Gesundheitsanwendungen) scheme remains the global benchmark for digital health integration, but it has shifted toward a "performance based" model. As of January 1st, 2026, at least 20% of the remuneration for each DiGA must be based on its actual performance. This requires manufacturers to conduct "accompanying success measurements" focusing on patient-reported health status, satisfaction and usage frequency. The scope of DiGA is also widening in 2026 to include Class IIb digital medical devices, providing a significant opportunity for companies developing higher risk therapeutic interventions. However, the requirement for local German data remains "non-negotiable" and foreign data is only accepted if comparability to the German context is rigorously proven. French Market Access: Liste en Sus and ASA Ratings In France, the Liste en Sus mechanism provides a critical "add-on" reimbursement for innovative medical devices in the inpatient setting, allowing them to be paid for separately from the standard hospital tariff. To be included, a device must demonstrate "actual benefit" (Service Attendu, SA) and, ideally, an "improvement of expected service" (ASA) rating of I, II, or III. Statistics from 2025 indicate that only 25% to 30% of products successfully achieve these higher ASA ratings, highlighting the intensity of the clinical dossier requirements. Pricing negotiations with the healthcare products pricing committee (CEPS) are increasingly focused on Total Cost of Care (TCOC) modelling, where a higher device price must be offset by a reduction in long-term complications or hospital readmissions. Reimbursement Benchmarks and Success Factors Country Pathway 2026 Requirement Update Success Driver Germany DiGA 20% performanc -based pricing. Local real-world evidence (RWE). France Liste en Sus Mandatory resubmission every 3 years. ASA I-III rating for premium pricing. UK NHS Procurement Focus on ICS (Integrated Care Systems). Alignment with elective backlog priorities. Belgium m-health National reimbursement launched 2025. Clinical utility for chronic disease. Netherlands DRG / GHS Yearly package releases. Proof of healthcare professional safety/satisfaction. Intellectual Property as a Strategic Asset In the medtech and healthtech sectors, intellectual property (IP) is often the most valuable asset, directly influencing investor confidence and long-term competitive positioning. In 2024, over 15,700 patent applications were filed with the European Patent Office (EPO) in medical technology, making it the second highest sector for filings after digital communication. The ratio of granted patents to applications in this field stands at a healthy 70.1%, significantly higher than in pharmaceuticals (36%) or biotechnology (22%). The launch of the Unitary Patent (UP) system has provided a transformative tool for European startups. A UP covers 18 EU Member States with a single application, offering substantial cost savings compared to traditional national validations.Medtech companies have enthusiastically embraced the UP, leading filings across all technical fields. This trend reflects a broader strategy of building "IP moats" that provide territorial coverage centrally at the Unitary Patent Court (UPC). Evolving Legal Standards for IP Portfolios Investors in 2026 are applying heightened scrutiny to the quality of patent claims. Following recent legal decisions, acquirers are wary of "functional genus" claims, claims that define an invention by what it does rather than what it is. For AI-enabled devices, patent strategies must emphasise the technical integration of AI, specifically how the algorithm drives a tangible modification in device operation, rather than claiming data processing in isolation. For a Series A round, a startup’s IP strategy should evolve through several stages: Early Stage: Focus on protecting core technology with a comprehensive initial application and initiating international filings. Mid-Stage (Series A/B): Pursue granted patents with diverse claim coverage, including future product iterations and core technology in key international markets. Risk Mitigation: Utilise patent watching services to track competitor IP and consider using the European opposition process to challenge the validity of threatening patents. Key Metrics for a HealthTech and MedTech company to raise a Series A round in Europe in today's environment Team Composition and the "Founder Banker" Era The European healthtech sector has moved into an era where "operational empathy" is a primary value proposition for both founders and advisors. Investors now prioritise teams that include senior commercial leaders with hospital network experience and digital health operators who have navigated payer reimbursement in multiple markets. The "Founder Banker", an advisor who combines deep technical fluency with investment banking expertise, has become a key architect of Series A and B liquidity. The Medical and Strategic Advisory Board (2026) Advisor Profile Key Requirement Strategic Rationale Commercial Scaling Global medtech P&L experience. Guide international go-to-market; manage large accounts. Regulatory Specialist Deep knowledge of MDR and AI Act. Navigate "Regulatory Darwinism"; manage NB audits. Digital Health Founder History of scaling to enterprise contracts. Avoid common pitfalls in payer adoption and retention. PE / M&A Advisor Life sciences transaction experience. Bridge the gap between VC growth and PE exit. Technical / AI Expert Generative biology or AI infrastructure background. Ensure architecture meets explainability and transparency needs. The emergence of "Clinical Co-Pilots" and "Vertical Intelligence" has also shifted expectations for technical leadership. Startups are increasingly expected to have a Chief Medical Officer (CMO) who is not just a scientific figurehead but a key driver of the clinical-technical integration, ensuring that AI tools solve actual operational inefficiencies for clinicians. Exit Pathways and the Series A Off-Ramp A defining thesis for 2026 is the "industrialisation" of the healthtech exit landscape. The traditional "escalator" model, where a Series A lead predictably to an IPO, has broken down for many. In its place, the "Series A Off-Ramp" has emerged, driven by the increasing involvement of private equity (PE) firms moving downstream to capitalise on depressed valuations and market fragmentation. PE-backed "buy-and-build" playbooks are particularly intense in healthcare services and IT. These buyers value companies on EBITDA multiples rather than the revenue multiples typical of venture capital, creating a friction point for founders with unrealistic valuation expectations. However, as runways dwindle, the certainty of a PE exit is becoming a viable strategic alternative to the uncertainty of the venture market. Strategic Acquirers and Transaction Contexts (2024-2025) Target Company Sector Acquirer Deal Context / Driver Shockwave Medical Cardio interventions Johnson & Johnson $13.1 Bn EV; category leadership. V-Wave Structural heart Johnson & Johnson Up to $1.7 Bn (milestone-structured). Exscientia AI Drug Discovery Recursion (US) Strategic merger; platform consolidation. Medifox Dan Care Software ResMed (US) $958M deal; US strategic expanding in Europe. Inveox Pathology / Medtech Undisclosed Insolvency sale; restructuring via proceedings. Consolidation of "point solutions" into comprehensive platforms is a major theme in 2026. Hospital CIOs report "vendor sprawl fatigue," leading to a preference for acquisitions that bundle multiple services into a single clinical layer. For a Series A company, being "acquirable" means demonstrating that the product can seamlessly plug into larger legacy stacks and provide immediate cross-selling opportunities for an incumbent's sales force. Regional Frontiers and Therapeutic Hotspots The European funding landscape remains concentrated in the UK, Germany, and France, but regional shifts are evident.The United Kingdom remains the leader, attracting $2.11 Billion in 2025, while Finland surged into second place ($1.16 Billion) due to the presence of large, established players like Oura Health. Southern Europe (Spain, Italy) is being recognised as a "growth frontier" for private equity, particularly in fragmented markets like dental and veterinary care where roll-up strategies are highly effective. In terms of therapeutic focus, oncology remains the top-funded area in Europe, attracting $515 Million in the first half of 2025, a 66% year over year increase. Cardiovascular diseases and dermatology also show strong momentum, while geriatrics has experienced explosive growth due to the pressures on hospital capacity and the rise of home-based care models. Therapeutic Investment Vectors and Risk Profiles (2026) Investment Vector Risk Profile Primary Investor Type Key Driver AI Infrastructure Low / Medium PE / Growth VC Workforce automation; recession resilience. Surgical Robotics High Deep Tech / Sovereign Funds Shift to ambulatory centers; cost containment. TechBio High Specialized VC / Pharma CVA Biopharma patent cliffs; pipeline velocity. FemTech (Menopause) Medium Growth VC / Corporate CVA Employer demand for benefits; demographic shift. Services Roll-ups Low Private Equity Multiple arbitrage; market fragmentation. FemTech has matured significantly, moving beyond generic wellness apps to precision medicine and specialised diagnostics. A winning commercial strategy in this space for 2026 is selling to employers as a corporate benefit (B2B2C), bypassing the difficult economics of direct-to-consumer (DTC) marketing. Synthesis: Navigating the New Series A Standard The successful European healthtech or medtech Series A in 2026 is defined by "technical defensibility and evidence maturity". To raise capital in this environment, founders must present a narrative that balances innovation with operational reliability. Capital now flows toward "predictable performance," and the market filters out ventures that fail to change clinical outcomes or system economics. A compelling Series A case must explicitly address the following: The Regulatory Moat: A clear, understandable path through MDR/IVDR and the EU AI Act, with high-risk designations used as a barrier to competition rather than an administrative burden. The EHDS Data Strategy: A plan to leverage the European Health Data Space for secondary data use, turning clinical data into a defensible asset for AI training and validation. Reimbursement and ROI: Hard data on health economic outcomes, using models that prove the solution reduces the total burden on the healthcare system. Workflow Integration: Technical architecture built for interoperability, ensuring that the solution creates zero friction for overloaded clinicians and hospital IT departments. The "Rule of 40" Trajectory: Financial projections that demonstrate a clear path to software-like margins, underpinned by high ARR per FTE and a high percentage of recurring revenue. In an environment where capital is concentrated and investors are increasingly selective, the primary asset of a startup is no longer its technology, but its "execution excellence". Those that can translate regulatory and commercial uncertainty into clear, clinically validated milestones will continue to secure the funding necessary to transform the European healthcare landscape. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Metrics for a HealthTech and MedTech company to raise a Series C round in Europe in today's environment Strategic Benchmarking for Series C Healthtech and Medtech Financing in the European "Industrial Maturity" Era The European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity. For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user acquisition or technological promise to a rigorous demonstration of unit economics, regulatory resilience, clinical validation and structural integration into healthcare systems. The defining thesis for venture capital and private equity in 2026 is the industrialisation of the sector, where valuations are no longer detached from the realities of reimbursement and clinical outcomes. This shift is necessitated by an elevated cost of capital and a "Great Capital Polarisation" that favours de-risked category leaders over smaller, unprofitable ventures. The Macro-Economic Architecture of European Health Funding The deployment of venture capital into the European healthtech and medtech sectors is currently shaped by a unique "use it or lose it" dynamic. Global private equity and venture capital firms are managing an unprecedented accumulation of unallocated capital, estimated at approximately $2.5 Trillion in dry powder. Much of this capital resides in vintage funds from the 2019–2021 fundraising cycle that are nearing the end of their investment periods, creating an intensified deal environment in late 2025 and throughout 2026. Despite this abundance of capital, investors have become significantly more discerning, moving away from a momentum driven approach toward a focus on differentiation, maturity and clear de-risking data. Investment Trends and Ecosystem Growth The European healthcare sector witnessed a dramatic resurgence in investment value during 2025. Total healthcare investment in Europe reached approximately €75.9 Billion across 870 deals, representing a 2.2-fold increase compared to the previous year. This robust growth is partly supported by the European Commission’s strategy to position the bloc as the world’s most attractive location for life sciences by 2030, a program backed by over €10 Billion in annual EU budget allocations targeting accelerated innovation and improved market access. Metric 2024 Performance 2025/2026 Performance/Outlook Source Total Healthcare Investment (Europe) €33.7 Billion €75.9 Billion Various Global Medtech Funding (H1) $13.6 Billion $15.4 Billion Various Median Medtech Financing Round $16.2 Million $36.0 Million Various European Digital Health Funding (Q1) $2.1 Billion $1.2 Billion (normalized) Various Value of VC-backed European Deep Tech $560 Billion $690 Billion Various Deep Tech Share of total European VC 15-19% 32-36% Various The rise in average round sizes, particularly a 122% increase in average financing rounds globally in 2025, highlights the concentration of capital in advanced-stage companies. In the medtech sector specifically, Series B and later rounds now account for nearly 65% of all activity, signaling that investors are waiting for significant de-risking before committing meaningful capital. This concentration has created a "Series B gap" where the average time to close a Series B round now approaches 30 months, reflecting the rigorous clinical and commercial hurdles that companies must clear to reach the scale required for a Series C. Geographic and Sectoral Shifts Europe currently accounts for approximately 24% of global healthcare volume by deal value. Within this landscape, the United Kingdom has emerged as the leading nation for healthcare investment, recording 145 deals worth €16.2 Billion in 2025. France and Germany maintain strong positions, though investment in these regions has shown signs of concentration in high-growth assets rather than broad-based volume. Finland has surged to a prominent position in Northern Europe, largely driven by mega-rounds such as Oura Health’s $900 Million financing. The sector is currently divided into three main pillars. Medical devices remain the most stable segment, drawing consistent funding for cardiovascular and robotic technologies. In vitro diagnostics (IVDs) are recovering after a post-pandemic slowdown and digital health is the fastest-growing area, rebounding to billions in global funding driven by telemedicine, AI and connected health platforms. Financial Benchmarks for Series C Readiness Raising a Series C round in 2026 requires meeting stringent financial performance standards that bridge the gap between high-growth startups and sustainable, scalable enterprises. Investors are prioritising "Efficient Growth," a concept that balances rapid expansion with disciplined capital management. The median annual growth for private software-based healthtech companies has decelerated to approximately 25%, making outperformance in growth a significant differentiator. The Rule of 40 and Efficiency Metrics The Rule of 40 has transitioned from a SaaS-specific metric to a universal baseline for late-stage healthtech and medtech viability. This metric offers a snapshot of a company’s financial health by combining its growth rate and profit margin. While a combined score of 40% or higher is generally considered healthy, the 2025–2026 healthtech cohort is performing significantly above this benchmark, with an average Rule of 40 score of 65%. For a Series C company, failing to meet the 40% threshold can lead to a 5x difference in valuation multiples compared to peers that exceed it. This reflects the market's low tolerance for "high-burn, high-growth" models that lacks a clear path to profitability. Operational and Unit Economic Benchmarks Investors in 2026 scrutinise unit economics to ensure that customer acquisition strategies are scalable and that the "Trust Gap", the lingering discount on healthtech valuations compared to general cloud software, can be overcome by superior retention and lifetime value. Metric Target Benchmark (Series C) Rationale Source ARR Range $15 Million – $50 Million Maturity milestone for late-stage venture Various LTV:CAC Ratio 4:1 (Target) / 3:1 (Floor) 3:1 is the minimum for scalable economics Various CAC Payback Period 12 – 14 Months Reflects tighter capital efficiency post-ZIRP Various Net Revenue Retention (NRR) >100% (Target 110%+) Proof of product-market fit and expansion Various ARR per Employee (FTE) $200K - $400K (SaaS) AI-native platforms target $500K-$1M Various Gross Margin (Subscription) 77% – 81% High-margin software is required for scale Various Burn Multiple < 1.0 (Target for scale-ups) Measure of capital efficiency in generating ARR Various The shift toward expansion revenue is a critical indicator of maturity. For companies with more than $50 million in ARR, expansion revenue typically represents over 50% of total new ARR, signaling that a company's existing customer base is its most reliable growth engine. This necessitates a mature customer success infrastructure and a product portfolio that supports cross-selling and upselling. The Regulatory Darwinism Framework In 2026, regulation is no longer viewed merely as a compliance obligation but as the primary determinant of asset value and a significant competitive moat. The market is undergoing a phenomenon described as "Regulatory Darwinism," where the ability to navigate complex EU regulations dictates which companies survive the transition to late-stage funding. EU MDR and IVDR Implementation Companies raising a Series C must have moved beyond the initial panic of transitioning from the older Medical Device Directive (MDD) to the more stringent Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Compliance Moats: Companies with MDR-ready hardware command revenue multiples of 3.5x to 5.5x, as the high regulatory barriers to entry prevent new competitors from easily entering the market. Notified Body Engagement: The process of (re-)certifying approximately 35,000 IVDs and a comparable volume of medical devices has placed immense strain on Notified Bodies. Series C companies must demonstrate a stable, long-term relationship with their Notified Body to ensure business continuity. EUDAMED Transition: Compliance with mandatory modules of the EUDAMED database is now required, shifting clinical and technical documentation toward a digitized, transparent system for European regulators. The EU AI Act and High-Risk Categorisation The EU AI Act reached full enforcement for "High-Risk" systems in March 2026, creating a binary filter for healthtech investment. Most medical AI tools fall into this high-risk category, necessitating: Data Governance and Transparency: Companies must meet stringent requirements regarding data sets, data lineage, and the technical documentation of algorithmic decision-making. Human Oversight: The design of AI systems must allow for meaningful human intervention and clear interpretation of outputs by clinical professionals. Technical Integration: To maximise valuation, AI-enabled devices should emphasise the technical integration of algorithms, specifically how they drive tangible modifications in device operation or clinical outcomes, rather than merely processing data in isolation. Market Access and Reimbursement Evolution The path to a Series C in Europe requires more than just regulatory approval; it requires a validated path to commercial reimbursement. The focus has shifted from "pilots" to "system impact," as health systems across Europe seek to integrate proven, cost-effective technologies. Germany's DiGA Framework Reform Germany remains the benchmark for digital health reimbursement through its DiGA (Digital Health Applications) pathway. However, the framework became significantly more demanding as of January 2026. Performance-Based Remuneration: At least 20% of a DiGA’s remuneration must now be linked to the actual performance and healthcare outcomes of the application. Success Measurement: Manufacturers are required to collect and provide quarterly data on usage duration, frequency, patient satisfaction and patient-reported health status. Clinical Evidence (pVE): The burden of proof for a "positive healthcare effect" remains high, requiring quantitative comparative studies, ideally prospective randomised controlled trials (RCTs), conducted within the German care context. The UK's NHS Scaling Problem and DTAC Standards The UK’s National Health Service (NHS) offers a massive potential market but is historically perceived as difficult to navigate. To address this, the NHS has standardised its assessment through the Digital Technology Assessment Criteria (DTAC). DTAC Version 2: Launched in February 2026, the updated criteria consolidate core standards across clinical safety, data protection, technical security, interoperability and usability. Clinical Safety (DCB 0129): Compliance with DCB 0129 is mandatory and requires the development of a Hazard Log, a Clinical Risk Management Plan, and oversight by a named Clinical Safety Officer. MedTech Funding Mandate (MTFM): This policy mandates local funding for NICE-approved technologies that are cost-saving within three years and have a national budget impact below £20 million. Successful scaling in the NHS often depends on achieving this mandate, as it bypasses local commissioning complexities. Technological Drivers of Valuation Premium The investment thesis for 2026 has moved beyond the "Chatbot" hype of previous years. Investors are no longer funding generalist models but are instead looking for "Vertical Intelligence" and clinical co-pilots that solve specific, high-value problems. AI-Native Infrastructure and "The Plumbing" While patient-facing apps dominated previous cycles, the "smart capital" in 2026 is flowing into the backend infrastructure of healthcare, described as the "plumbing" that enables data interoperability. Curated Clinical Data: By mandating that hospitals and clinics make health data available for secondary use, the EU has effectively created a new asset class: Curated Clinical Data. Efficiency as Clinical Priority: With a shortage of 1.2 Million healthcare workers across Europe, solutions that automate documentation or reduce nurse staffing ratios command the highest valuation premiums. Precision Medicine and Femtech 2.0 The menopause opportunity has emerged as a major thematic pillar. By 2030, over 1 Billion women globally will be perimenopausal or menopausal, a demographic at the peak of their earning power that has been historically underserved. B2B2C Business Models: The winning strategy for 2026 is selling women's health support as a corporate benefit. This approach, used by leaders like Peppy and Maven, bypasses the difficult unit economics of direct-to-consumer marketing and aligns with corporate retention goals. Diagnostic Innovation: Startups are moving Femtech into rigorous diagnostics, utilizing novel form factors (e.g., tampons for microbiome screening) to provide clinical-grade data. Robotics and Minimally Invasive Surgery Robotics and cardiovascular devices continue to outpace the broader market in terms of both funding and valuation. High-growth procedural segments like neuro-stimulation, pulse field ablation and structural heart solutions are attracting significant interest from both private equity and large-cap strategics. The valuation impact is tied to the technology's ability to shift procedures to ambulatory surgery centres or improve surgical precision, thereby reducing overall system costs. Strategic Intellectual Property and Portfolio Management For Series C healthtech and medtech companies, maximising valuation in 2026 requires a shift toward a sophisticated intellectual property (IP) strategy that protects both the technology and the regulatory "moat". The Amgen Enablement Standard Following the US Supreme Court’s decision in Amgen Inc. v. Sanofi, patent portfolios are under intense legal scrutiny. Acquirers and late-stage investors are increasingly wary of "functional genus" claims, claims that define an invention by what it does rather than what it is. Structural Disclosure: To support high valuations, companies must ensure their patent specifications provide full structural disclosure commensurate with the scope of the claims. Enablement Threshold: Reliance on broad functional language without detailed technical specifications presents a substantial risk to the "investability" of a platform technology. Coordination of Patent and Regulatory Moats A crucial, often overlooked metric for Series C readiness is the consistency between IP filings and regulatory submissions. Consistency Risk: Arguments made to patent offices regarding "novelty" must not contradict "substantial equivalence" assertions made to regulators like the FDA to secure faster 510(k) clearance. Patent Term Protection: Strategically structuring parent and child applications is essential to protect the "commercial tail" of the patent term, particularly for products with long clinical development cycles. Design Patents: The 2025–2026 market has seen a surge in the use of design patents as enforcement tools, as they can be more decisive in securing import bans through the International Trade Commission (ITC) than complex utility patents. Key Metrics for a HealthTech and MedTech company to raise a Series C round in Europe in today's environment Valuation Multiples and Exit Dynamics The valuation landscape in late 2025 and 2026 reflects a "new normal" where multiples are grounded in fundamental business metrics rather than speculation. While general medtech multiples have stabilised, innovators in AI and digital surgery command significant premiums. Revenue and EBITDA Multiples by Sub-Sector The market hierarchy in 2026 reveals a clear preference for asset-light, high-growth, and recurring revenue models. Sub-Sector EV/Revenue Multiple (2026) EV/EBITDA Multiple (2026) Valuation Drivers Source AI-First Drug Discovery 8.0x – 15.0x N/A (Pipeline-based) Upfront payments and R&D speed Various Premium AI & Data Platforms 6.0x – 8.0x 15x – 18x Proprietary datasets and Rule of 40 Various Value-Based Care Solutions 5.5x – 7.0x 12x – 15x Demonstrable ROI for payers Various MedTech Hardware (MDR-Ready) 3.5x – 5.5x 11x – 14x Strategic compliance moats Various General HealthTech SaaS 4.0x – 6.0x 10x – 13x Predictable unit economics Various Small/Unprofitable Startups 3.0x – 4.0x N/A Valuation compression Various Publicly traded medtech companies such as Siemens Healthineers (3.6x revenue) and Straumann (5.5x revenue) provide a baseline for established entities, but private Series C "champions" often command premiums if they can demonstrate higher growth endurance and superior technical talent. The M&A and IPO Landscape The IPO market, while stagnant for much of the previous three years, showed signs of recovery in late 2025 with significant debuts like Medline on the Nasdaq. However, M&A remains the primary exit path for European healthtech. Strategic vs. Financial Buyers: Private equity firms, possessing significant "dry powder," are paying premiums for stable, cash-flowing assets, with median EV/EBITDA multiples around 11.2x. Corporate acquirers are focusing on "capability-building" acquisitions that strengthen their positions in high-growth procedural segments. The Trust Gap: Despite strong performance, healthtech 2.0 stocks often trade at a discount compared to general software, a legacy of the 2020-2021 market correction. To maximise exit value, Series C companies must articulate a clear, evidence-backed value creation story. Conclusion: The Series C Playbook for 2026 To successfully raise a Series C round in the current European environment, companies must present a profile that balances technological innovation with industrial maturity. The metrics of success have evolved from simple growth to a multi-dimensional assessment of capital efficiency, regulatory strength and clinical integration. The "Golden Standard" for a Series C company in 2026 includes a Rule of 40 score exceeding 60%, an LTV:CAC ratio above 4:1 and a clear "compliance moat" established through early and proactive alignment with the EU AI Act and MDR/IVDR. Geographically, while the UK continues to lead in volume, the ability to navigate the complex reimbursement landscapes of Germany (DiGA) and the UK (NHS) remains the ultimate proof of a scalable business model. Ultimately, the market has transitioned to a "winner-takes-most" environment. Capital is no longer flowing to speculative bets but is instead concentrating in a handful of category leaders who can demonstrate "Hard ROI" and a structural integration into the future of healthcare. For the companies that can clear these high bars, the availability of $2.5 Trillion in unallocated capital ensures that the rewards for success are greater than ever before. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Metrics for a HealthTech and MedTech company to raise a Series B round in Europe in today's environment Performance Benchmarks and Capital Efficiency Requirements for European HealthTech and MedTech Series B Financing in 2026 The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of speculative experimentation into what industry analysts categorise as the era of industrial maturity. This evolution is characterised by a "flight to quality," where the market has bifurcated into a high-conviction environment for category leaders and a severe capital squeeze for mid-stage ventures that fail to demonstrate immediate, systemic value. As the aggregate data suggests a resilient recovery, evidenced by European digital health funding rising to an estimated $6.2 Billion in 2025, the underlying mechanics of the Series B round reveal a persistent "Series B Gap," with the time to close funding rounds now approaching 10 to 12 months. Investors are no longer captivated by technological promise in isolation; instead, they prioritise deep integration into clinical workflows, robust unit economics and a transparent path to profitability. The Macroeconomic Context of the 2026 European Series B Landscape The transition into 2026 represents a departure from the "growth at all costs" paradigm that defined the zero-interest-rate policy (ZIRP) era. In the current landscape, the cost of capital remains elevated, forcing a recalibration of investment criteria toward "Industrialisation", a concept signifying that startups must serve as essential infrastructure rather than discretionary software layers. Global digital health venture funding reached $7.1 Billion in Q1 2026 across 216 deals, reflecting a modest year-on-year decline of 6.6% in value but a staggering 48.6% decline in deal count. This indicates a profound concentration of capital: while fewer deals are being struck, the average VC deal size has surged to $38.4 Million globally, up significantly from $21.4 Million in early 2025. In Europe, the Q1 2026 funding metrics reveal a similar trend of disciplined maturation. The ecosystem deployed $1.2 Billion in venture capital across 67 active deals. While this value represents a decline from the exuberant highs of early 2025, the average European deal size has climbed to $21.1 Million. The funding distribution by stage underscores the dominance of growth-stage ventures, which absorbed $622 Million of the quarterly total, compared to $378 Million for early-stage and only $116 Million for late-stage rounds. European Digital Health Funding Metric (Q1 2026) Value Trend vs. Q1 2025 Total Venture Funding (Excl. Exits) $1.2 Billion ↓ 44% VC Deal Count 67 ↓ 46% Average VC Deal Size $21.1 Million ↑ 8% Mega-Deals (≥$100M) 3 Stable Growth-Stage Capital Share $622 Million Dominant This liquidity cycle is further shaped by an unprecedented accumulation of unallocated capital, with global private equity funds sitting on nearly $2.5 Trillion in "dry powder". Much of this capital is allocated to vintage funds from the 2019–2021 cycle that are nearing the end of their investment periods, creating a "use it or lose it" dynamic expected to intensify deal activity throughout 2026. However, this capital is increasingly focused on defensive moats, specifically clinical validation and regulatory status, as the primary currencies of value. Financial Benchmarks: The Pivot to EBITDA and the Rule of 40 For Series B companies in 2026, the metric of choice for both private and public investors has shifted definitively toward EBITDA or a highly credible, near-term trajectory toward it. The "Rule of 40," which traditionally balanced growth and profitability, has seen its internal weighting shift heavily toward the profit component. In previous cycles, a venture might satisfy investor demands with 50% growth despite -10% margins; in 2026, such high-burn profiles face revenue multiple compression into the 3x–4x range, whereas moderate growth platforms demonstrating consistent profitability command premiums of 10x–14x EBITDA. The Rule of 40 and Performance Tiers The Bessemer Health Tech Index and other 2026 benchmarks identify a "Health Tech 2.0" cohort that consistently outperforms broader SaaS indexes. Investors at the Series B stage now look for "sustained hypergrowth" characterised by year-over-year revenue growth exceeding 150% and net revenue retention (NRR) above 120% to justify billion-dollar valuations at a $30 Million ARR run rate. Revenue and Growth Requirements for European Series B Raising a Series B round in the 2026 environment requires a baseline of commercial traction that would have been sufficient for a Series C round just three years prior. For HealthTech and digital health companies, the annual run-rate revenue (ARR) requirement typically sits between $10 Million and $30 million, with a mandatory year-over-year growth rate of 80% to 100%. Metric Category Series A Median Series B Best-in-Class (2026) Strategic Signal ARR Growth (YoY) 80% – 100% >150% Top-of-funnel efficacy Net Revenue Retention 100% – 105% >120% Product-market fit; expansion Gross Margin 68% – 72% >80% Unit economics ceiling ARR per FTE $200K – $400K $500K – $1M+ AI-driven productivity In the MedTech hardware sector, where regulatory barriers are higher, the revenue requirements for an equivalent funding round are often lower in absolute terms, typically $5M to $15M, but are paired with more stringent clinical evidence and regulatory milestones. The Health AI X-Factor: Productivity as a Valuation Multiplier The implementation of artificial intelligence has moved beyond experimental pilots to become a fundamental valuation multiplier in 2026. The "Health AI X-Factor" framework identifies companies that deserve a premium based on their ability to achieve unprecedented efficient growth and platform expansion. AI-native healthcare companies are now reaching $100 Million to $200 Million in ARR in under five years, significantly faster than the 10+ years typical for previous healthcare software generations or the seven years common for broader cloud companies. ARR per Full-Time Employee (FTE) The most critical metric reflecting this shift is the evolution of ARR per FTE. Traditional healthcare services generate $100,000 to $200,000 in ARR per employee, whereas AI-native platforms are achieving metrics between $500,000 and over $1 Million. This productivity leap allows for software-like margins even at an industrial scale, justifying the premium valuations observed for AI-first drug discovery and imaging assets. Maturity Category ARR per FTE Benchmark Valuation Multiple Context Traditional Healthcare Services $100K – $200K Low (3x – 6x EBITDA) Healthcare SaaS (Legacy) $200K – $400K Moderate (10x – 13x EBITDA) AI-Native Platforms $500K – $1M+ High (15x – 18x+ EBITDA) Investors scrutinise whether AI is embedded in mission-critical workflows, such as imaging, revenue cycle management (RCM), triage and operational optimisation, rather than existing as a peripheral feature. Assets with proprietary, clinically validated datasets and AI that demonstrably improve workflow or outcomes command a clear premium, often 20–30% higher EV/revenue multiples than non-AI peers. Segment-Specific AI Multiples In 2026, the valuation of AI assets is heavily influenced by the specific domain of application and the associated regulatory or reimbursement clarity. AI Market Segment EV/Revenue Multiple Primary Valuation Drivers AI-First Drug Discovery 8.0x – 15.0x "Bio-bucks" potential; reduced R&D costs AI-Enabled Clinical Trial Ops 7.0x – 12.0x Speed to market; patient matching accuracy AI-Powered Medical Imaging 5.0x – 9.0x FDA/EMA clearance; radiologist efficiency AI Remote Monitoring 4.0x – 8.0x Scale (>100k lives); reduction in staffing Operational & RCM AI 3.0x – 6.0x Administrative relief; autonomous billing Capital Efficiency and the Burn Multiple In 2026, capital efficiency has replaced growth rate as the primary determinant of whether a Series B term sheet is issued.The "Burn Multiple", defined as net cash burned divided by net new ARR, has become the shorthand metric VCs use to judge capital discipline. A burn multiple of 1.0x means a company is spending one dollar to generate one dollar of new ARR. In the 2026 environment, a burn multiple below 1.5x is considered strong, while a multiple above 2.0x is a significant red flag for Series B investors. AI-native SaaS companies are setting a higher bar, achieving burn multiples of 0.8x to 1.2x. Unit Economics: LTV:CAC and Payback Periods The LTV:CAC ratio remains the floor for evaluating whether unit economics will work at scale. For a Series B company in 2026, an LTV:CAC ratio of 3:1 is the absolute minimum, while top-quartile companies maintain 4:1 to 6:1. Funding Stage / Motion Typical CAC (Order of Mag) Typical Payback Typical LTV:CAC Seed / Bootstrap (Self-Serve) £200 - £600 6 - 9 Months ~4.0x Series A (Repeatable Channels) £800 - £1,500 9 - 15 Months ~3.5x Series B (Enterprise Sales-Led) £2,500 - £6,000 12 - 24 Months ~3.0x The CAC payback period, the number of months required to recover the cost of acquiring a customer, is the single clearest signal of go-to-market efficiency. For Series B ventures, investors favour a payback period under 12 months, although enterprise motions can stretch to 24 months if retention is exceptionally strong and expansion revenue is real. Regulatory Darwinism: The Compliance Moat as a Financial Asset One of the most profound shifts in the 2026 valuation landscape is the emergence of "Regulatory Darwinism". Regulatory status has surpassed traditional financial metrics to become the single most critical filter for acquisition and investment. In 2026, a valid MDR/IVDR certificate is no longer merely a permit to sell; it is a significant financial asset that creates a defensible competitive moat. The Triple Regulatory Convergence of 2026 Three major regulatory milestones have converged in 2026 to redefine deal value and timing for European HealthTech and MedTech companies : MDR/IVDR Full Enforcement: Class III custom-made devices must reach full compliance by May 26th, 2026. The scarcity of Notified Bodies has led to an 18–24 month regulatory risk profile for non-certified devices, making those with existing certifications highly sought after. The EU AI Act: Full enforcement for "high-risk" medical AI systems began in early 2026. Investors are rigorously avoiding "black box" models, favouring ventures that have engineered "glass box" interpretability to satisfy transparency and data governance requirements. Mandatory EUDAMED Usage: The European Database on Medical Devices (EUDAMED) became fully functional and mandatory as of May 28, 2026. This requires significant system integration, serving as an operational filter for startups. Regulation Implementation Milestone (2026) Impact on Series B EU MDR Transition ends May 28, 2026 Non-compliant devices removed from market EU IVDR Transition ends May 28, 2026 Critical for all diagnostic startups EU AI Act High-risk obligations apply August 2026 Mandatory bias control & human oversight EUDAMED Modules 1, 2, 3, 5 mandatory May 2026 Full digital transparency required Clinical Evidence Maturity A believable regulatory plan tied to FDA or EMA pathways is a prerequisite for Series B in 2026. Investors heading into 2026 want early signals that a product works in real settings through pilot data, small observational studies, or performance benchmarks against standard-of-care tools. For MedTech diagnostics, this translates to a rigorous accumulation of regulatory approvals and peer-reviewed publications; in 2025 alone, the top 50 European healthtech startups achieved 40 regulatory approvals and 21 clinical trials. Commercial Validation and Reimbursement Pathways Reimbursement determines whether a device gets used, while the CE mark only opens the market. Each major European market operates independent national reimbursement systems with distinct timelines and evidence requirements. Germany: DiGA and NUB Germany's DiGA pathway remains the fastest reimbursement route for software medical devices (SaMD) in Europe, allowing listing in the BfArM directory within three months. Eligibility Expansion: Starting in 2026, eligibility will extend to include Class IIb devices, significantly widening the opportunity for complex digital therapeutics. Evidence Mandate: Every DiGA must demonstrate a positive healthcare effect (pVE), either a medical benefit (mN) or a patient-relevant structural and procedural improvement (pSVV). Local Data Requirement: Studies must generally be conducted in Germany to reflect local care populations and provider interactions. Foreign data is only acceptable if comparability is rigorously demonstrated. UK: National Healthtech Access Programme (NHAP) On February 9th, 2026, the UK launched the National Healthtech Access Programme (NHAP), which fundamentally changes how medical technology is funded. The NHAP expands NICE's Technology Appraisals programme to include health technologies, meaning a selection of high-impact medical devices, diagnostics, and digital tools will be reimbursed and made available consistently across the entire NHS. UK Pathway Focus / Stage Evidence Requirement NICE EVA Early Value Assessment Limited evidence; provisional NHS access NICE MTA MedTech Assessment Full HTA using QALY framework; 18-36 months NHAP National Access Programme Selected high-impact, cost-effective tools Joint Clinical Assessments (JCA) The Health Technology Assessment Regulation (HTAR) aims to standardise clinical evaluations through Joint Clinical Assessments starting in 2026 for high-risk medical devices and IVDs. This shift aims to stabilise the system while a broader revision of the MDR and IVDR remains the ultimate priority. Key Metrics for a HealthTech and MedTech company to raise a Series B round in Europe in today's environment MedTech Hardware vs. HealthTech SaaS: Divergent Benchmarks The 2026 market recognises distinct financial and operational profiles for MedTech hardware and HealthTech SaaS.MedTech companies, often building deep tech or robotics, are evaluated on procedural volume and clinical precision rather than pure subscriber growth. IPO and M&A Readiness Thresholds Rigorous financial benchmarks have been established for companies seeking exits or late-stage growth rounds. Metric MedTech (Hardware) HealthTech (Digital Health) Min. Annual Run-Rate Revenue $40M–$60M+ $200M+ Target Gross Margin 65%–80% 60%–80% (Hinge Health: 83%) Required Growth (2–3 yr CAGR) 25%–30% 20%–25% Profitability Target EBITDA positive trajectory Non-GAAP Op. Income or FCF+ MedTech hardware that is MDR-ready commands 3.5x to 5.5x revenue multiples and 11x to 14x EBITDA, reflecting high regulatory barriers and the strategic "compliance moat". In contrast, premium AI and data platforms in HealthTech can stretch to 6.0x–8.0x+ revenue multiples due to their scalability and proprietary clinical datasets. Biotech Series B Benchmarks Biotech valuations in 2026 are anchored in tangible scientific progress rather than today's revenue. Strong Series B biotech companies in 2025–2026 have often exceeded $150 million in valuation. Clinical Advancement: Investors prioritise companies showing positive Phase 2 or early Phase 3 trial data. Valuation Methodology: The industry standard is the Risk-Adjusted Net Present Value (rNPV), using probability-weighted cash flows based on clinical trial success rates, with discount rates typically averaging around 19%. Provider Adoption and Operational KPIs As health systems enter 2026, digital transformation is no longer measured by tool deployment but by deep and broad adoption. C-suites track the percentage of eligible encounters where a tool is activated during a real decision making window, such as an order placed or a discharge finalised. The AI Readiness Gap in Health Systems While 85% of healthcare organizations adopted or explored AI by the end of 2024, only 18% were actually ready to deploy AI in care delivery as of early 2026. Organisations that successfully integrate advanced analytics see an average ROI of 147% within three years. However, the cost of data breaches—averaging $7.42 Million per incident and the presence of "shadow AI" in 40% of hospitals create significant regulatory and financial hurdles. Patient Engagement and Clinical Outcome Benchmarks The healthcare industry's shift toward value-based and patient centred care models is the primary driver of the patient engagement technology market, which is projected to grow from $41.3 Billion in 2026 to $193.22 Billion by 2034. Patient Activation and Utilisation The Boston Medical Center research highlights that highly activated patients (PAM Level 4) have approximately 43% lower rates of 30-day post-discharge hospital utilisation than the lowest activation patients. PAM Level Patient Behaviour Profile Engagement Risk Level 1 Passive; relies entirely on provider Highest Level 2 Aware but lacks confidence to act High Level 3 Beginning to take action but inconsistent Moderate Level 4 Proactive; maintains healthy behaviours Low Clinics that invest in structured engagement infrastructure, such as automated recall, digital intake and two-way messaging, outperform those relying on ad-hoc communication. Appointment reminders via SMS consistently rank as the highest-ROI engagement touchpoint for reducing no-show rates, which typically range from 10-30% in private clinics lacking such tools. Regional Ecosystem Analysis: Concentration of European Innovation The European HealthTech market in 2026 is at a pivotal juncture, with success predicated on navigating a landscape defined by regulatory maturation and selective funding. The European digital health market, valued at $96.68 Billion in 2025, is projected to reach $222.22 Billion by 2030, advancing at a CAGR of 18.11%. Geographic Powerhouses and Funding Trends The distribution of capital remains highly concentrated in the United Kingdom and Northern Europe. United Kingdom: Remains the regional leader, attracting $2.11 Billion in funding. Its ecosystem is supported by AI-enabled pathways that have reduced clinical trial approval timelines. Finland: Surged into second place with $1.16 Billion, heavily influenced by the Oura Health mega-round. France and Germany: Experienced funding declines in 2025, falling to $731 Million and $612 Million, respectively, suggesting investor concentration around specific high-growth assets. Southern Europe: Emerging as the "growth frontier" for private equity roll-ups in fragmented markets like dental and veterinary clinics. The Role of Foreign Capital By early 2026, funding dynamics have been reshaped by aggressive US capital entry, with US investors accounting for 61% of late-stage deals, up 20 percentage points from 2024. This "American Underwriter" dynamic has introduced "American-style" pricing to European ventures but also raises questions about whether the ecosystem can generate exits that justify such valuations in a fragmented regulatory environment. Venture Capital Deal Terms and Governance in 2026 The Series B deal terms in Europe for 2026 reflect an investor preference for safer bets and companies with proven track records. The broader trend of increased cost of capital is reflected in both financing valuations and the structural protections embedded in term sheets. Investor Safeguards: Liquidation and Anti-Dilution Liquidation preferences have become market standard, with a 1x non-participating preference being the most common protection. Participating Preferences: These continue to be an anomaly in healthy rounds, typically reserved for distressed or high-risk scenarios. Anti-Dilution Clauses: Weighted-average formulas are widely used to calculate the subscription price in a subsequent down round. Broad-based protection is more favourable to existing investors as it includes the fully diluted issued share capital in the denominator. Pay-to-Play: These clauses, which incentivise existing investors to participate in down rounds by granting them continued economic rights, are less common in Germany and France than in the US market. Leaver Provisions and Founder Revesting Governance requirements often differ between US-led and European-led rounds. In the US, the default assumption is that a departing founder is a "good leaver", they keep their vested equity unless there is fraud or willful misconduct.European rounds are more likely to include broader "bad leaver" provisions, potentially allowing investors to reclaim a portion of equity in wider circumstances. Term 2026 Market Standard (Series B) Founder Impact Liquidation Preference 1x Non-Participating Protects downside; pro-rata above 1x Anti-Dilution Weighted-Average Moderate dilution in down rounds Dilution at Series A/B ~20% per round Standard market expectation Leaver Provision US-Style "Good Leaver" default Retain vested equity unless misconduct The Exit Landscape: M&A, IPOs, and Consolidation Exit activity remained subdued in early 2026 compared to peak years, with strategic and sponsor-backed M&A continuing to dominate. Large-cap healthcare companies, having avoided transformational deals in 2024 and 2025 are now re-entering the market to optimise their portfolios. M&A Trends and Specialisation Acquirers are prioritising capability-building acquisitions that strengthen their positions in high-growth procedural segments like sports medicine, cardiovascular and neuro-stimulation. Specialty Practice Sub-Sector EV/Revenue (Typical) EV/EBITDA (Typical) Growth Catalyst Cardiology 1.0x – 1.5x 8x – 11x Integration of monitoring tech Oncology 0.9x – 1.3x 8.0x – 8.5x Clinical complexity; reimbursement Orthopedics 0.8x – 1.2x 7x – 10x Ambulatory surgery shift Gastroenterology 0.8x – 1.2x 8x – 10x High procedure volume; PE interest Primary Care 0.5x – 0.7x 3x – 5x Value-based care targets The Persistence of the "Trust Gap" Despite showing metrics that rival or exceed high growth software companies, such as twice the revenue growth and stronger FCF margins, health tech stocks still trade at a 10–20% discount to their cloud counterparts. This "trust gap" lingers from the 2020–2021 market correction, though 2025 saw a strong recovery for "Health Tech 2.0" stocks, which rose 18% in line with the NASDAQ. Conclusion: Strategic Imperatives for European Series B Success The European HealthTech and MedTech sectors enter the second half of 2026 at a profound inflection point. The speculative fragmentation of the early 2020s has given way to an "Industrialised" era where clinical validation and regulatory moats are the primary currencies of value. For founders, the strategic mandate is clear: compliance is not a mere cost of doing business but a critical competitive advantage, and business models must demonstrate tangible, evidence-based value to unlock capital. To successfully raise a Series B round in this environment, ventures must hit the following targets: Capital Efficiency: Maintain a burn multiple below 1.5x and a CAC payback under 12-15 months. Productivity Leap: Achieve $500k+ ARR per FTE through AI-native integration into mission-critical clinical or administrative workflows. Regulatory Maturity: Secure full MDR/IVDR compliance before mandatory deadlines and align with the EU AI Act's data governance standards. Commercial Moat: Secure early signals of reimbursement (e.g., DiGA listing or UK NHAP inclusion) and demonstrate a clear ROI for providers through first-pass claim success or clinician time savings. Ultimately, a simpler and more predictable system is not a shortcut on safety but the condition for safety, timely patient access, and Europe's long-term competitiveness in a global market increasingly defined by evidence-backed innovation. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

IBM is re-entering the healthcare space: Less "Jeopardy!" and more "Efficiency" The Industrialisation of Healthcare AI: IBM’s Strategic Pivot to Secure Hybrid Infrastructure and Operational Efficiency in 2026 The healthcare industry in 2026 has transitioned from a period of experimental artificial intelligence fervour to a phase of rigorous industrialisation, where the value of technology is measured by its ability to stabilise margins and secure sensitive data rather than its capacity for high-profile public spectacle. International Business Machines (IBM), having navigated a decade of volatility in its Watson Health division, has executed a profound strategic re-entry into the sector. This shift is defined by a move away from being the clinical "face" of healthcare AI, once epitomised by the Jeopardy winning Watson, toward becoming the "neutral plumbing" of the industry: the secure, hybrid-cloud infrastructure foundation that enables hospitals to run their AI ecosystems with verifiable safety and predictive economics. In a climate defined by severe workforce shortages and acute margin pressure, hospitals are increasingly rejecting monolithic, proprietary "black box" solutions in favour of open, interoperable platforms that prioritise backend efficiency and data sovereignty. The Institutional Collapse of Cognitive Computing: A Strategic Post-Mortem The current 2026 strategy is rooted in the lessons learned from the "cognitive computing" fallacy that dominated IBM's previous healthcare efforts. The original Watson Health era, which peaked between 2015 and 2021, was characterised by a fundamental misunderstanding of the clinical domain's complexity. While the Watson supercomputer excelled at parsing static, encyclopaedic factoids for competitive trivia, it proved fundamentally ill-equipped for the non-deterministic, nuanced decision-making required in oncology and genomic medicine. The institutional collapse of Watson Health was not merely a failure of algorithms but an operational mismatch between marketing hyperbole and clinical reality. Research into the Watson failure identifies the "technical paradox" of natural language processing (NLP) in clinical settings. Approximately 80% of all healthcare data remains unstructured, held in pathology reports, discharge summaries, and handwritten notes. Watson’s NLP architecture struggled to distinguish between a patient’s historical medical events and their current acute symptoms, often providing recommendations that were inappropriate or unsafe. Furthermore, the reliance on synthetic data trained by a narrow group of elite physicians at Memorial Sloan Kettering Cancer Center (MSKCC) created an inherent bias that made the system incompatible with the protocols of community hospitals and international healthcare systems. In June 2022, IBM divested the assets of Watson Health to Francisco Partners, rebranding the remains as Merative and signalling the end of IBM’s direct clinical tool development. CEO Arvind Krishna explicitly stated that the company lacked the requisite "vertical expertise" for healthcare, choosing instead to refocus on horizontal AI and hybrid cloud offerings. This divestiture served as a "clearing of the decks," allowing the company to shed billions in underperforming acquisitions and pivot toward the 2026 "Efficiency" model. Metric Watson Health Era (2015-2022) Infrastructure Era (2026) Operational Focus Clinical Diagnosis & Oncology System-wide Efficiency & AIOS Architectural Model Monolithic "Black Box" Open, Modular Hybrid Cloud Data Philosophy Centralized Cloud Ingestion Move AI to the Data (On-Prem/Edge) Primary Goal Replacing Human Expert Tasks Redesigning the Business Model Regulatory Approach Static Policy Statements Runtime Sovereignty Enforcement Interoperability Low (Siloed within IBM) High (Standardized MCP/Layer 8) The 2026 Macroeconomic Imperative: Why Hospitals Prioritise Efficiency The re-entry of IBM as an infrastructure provider aligns with a period of unprecedented financial strain for health systems. In 2026, US healthcare spending is projected to reach $5.7 Trillion, yet many hospitals operate on razor-thin margins, with median growth for 450 of the Fortune 500 companies remaining in the single digits. The industry is facing a global shortfall of 18 Million healthcare workers by 2030, a crisis that has elevated the reduction of "administrative toil" from a tactical goal to a survival imperative. The "Efficiency" model appeals to these cash-strapped entities by targeting the revenue leakage and operational waste that plagues manual processes. Statistical analysis of 2026 healthcare operations reveals the depth of this challenge: Denied Claims: Hospitals spend approximately $19.7 Billion annually trying to overturn denied claims, with each claim costing $118 to process. Workflow Inefficiency: Initial claim denial rates have climbed to 11.8%, with 86% to 90% of these denials classified as avoidable through better data automation. Shadow AI Risks: Shadow AI, unauthorised AI usage by clinicians, is present in 40% of hospitals, adding an average of $670,000 to the cost of data breaches. Breach Penalties: The average healthcare data breach cost has risen to between $7.42 million and $10.9 million per incident. In this context, hospitals are increasingly wary of "AI tourists", providers offering shallow pilots that fail to scale.Instead, they are seeking "neutral plumbing" that can integrate disparate agents, manage non-human identities, and enforce compliance at the infrastructure level. The AI Operating Model: Layer 8 and the AIOS Architecture IBM’s 2026 Technology Atlas for Hybrid Cloud outlines a paradigm shift from individual AI models to integrated AI systems that function as an "Operating System for AI" (AIOS). This architecture is built on the premise that AI innovation has entered a new application and protocol layer, often referred to as "Layer 8". This layer evolves middleware to manage the entire stack: models, tools, persistence, and application orchestration. The Model Context Protocol (MCP) A central pillar of the infrastructure re-entry is the adoption of the Model Context Protocol (MCP). In a heterogeneous hospital IT environment, connecting 20 different AI models to 20 legacy enterprise systems (EHRs, PACS, RCM platforms) could require up to 400 custom connectors. The MCP eliminates this "NxM problem" by acting as a universal translator and traffic controller. The MCP allows AI agents to securely and dynamically interact with trusted data sources in real-time, facilitating standards-based access to clinical evidence. As of early 2026, 80% of Fortune 500 companies are deploying active AI agents, with 28% having already implemented MCP servers to unify their data ecosystems. Early deployments indicate substantial operational gains, including up to 70% reduction in AI operational costs and 40% faster agent deployment. Real-Time Data Streaming via Confluent The $11 Billion acquisition of Confluent is regarded as IBM’s most strategically significant "plumbing move" of the current cycle. Traditional enterprise architectures were built for batch processing, which creates latencies incompatible with real-time patient monitoring. Confluent provides the streaming, governed and contextual data required for agentic AI to act "in the moment". By integrating Confluent's Tableflow with watsonx.data, real-time streams of clinical data are made immediately available as open table formats for analysis. This enables a shift from "passive monitoring" to "intelligent response," where the network can detect actual system-to-system communications and identify anomalies that human telemetry sources often miss. Component Technical Function Impact on Hospital Efficiency watsonx.data Hybrid, Open Lakehouse Unified access to structured and unstructured datasets across multi-cloud environments. watsonx.ai Model Tuning & Deployment Fine-tuning domain-specific models (like Granite) on private clinical data. watsonx Orchestrate Agentic Control Plane Managing fleets of agents to handle referrals, scheduling, and RCM. IBM Concert Intelligent IT Operations Correlating signals across apps and infrastructure to reduce recovery time. IBM Sovereign Core Operational Independence Verifying control over where models run and how inference is governed. Operational Sovereignty: Securing the Regulated Frontier Digital sovereignty has moved from a regulatory compliance checkbox to a strategic differentiator in 2026. For healthcare providers, sovereignty now extends beyond simple data residency to include control over infrastructure operations and AI system behavior. IBM Sovereign Core, which became generally available in May 2026, was designed specifically for organisations in critical infrastructure sectors that cannot compromise on authority over their digital estates. The Four Pillars of Digital Sovereignty IBM defines digital sovereignty across four core domains, each of which addresses a specific vulnerability in modern hospital cloud adoption : Operational Sovereignty: Control over how environments are operated, including a customer-operated control plane that allows the hospital full authority over configurations and lifecycle management. Data Sovereignty: Direct control over data at rest, in use, and in motion, utilising in-boundary encryption and "Keep Your Own Key" (KYOK) technology. Technology Sovereignty: An open, modular architecture based on Red Hat OpenShift that avoids vendor lock-in and ensures workload portability across private and public clouds. AI Sovereignty: Precise control over where models run and how inference is governed, ensuring that AI reasoning occurs within defined jurisdictional boundaries. Verifiable Compliance Evidence For regulated entities, sovereignty must be observable and provable to auditors. Sovereign Core provides continuous integrated monitoring and automated evidence generation, mapping system operations against 160 global regulatory frameworks, including GDPR, HIPAA, and the EU AI Act. This eliminates the manual burden of periodic, point-in-time audits, which currently consume a disproportionate share of hospital IT budgets. Sovereignty Feature Technical Implementation Benefit to Regulated Entities In-Boundary Identity Localized Secret Manager Authentication remains within the perimeter, preventing external access. Drift Detection Real-time policy monitoring Immediate alerts if AI model behavior deviates from clinical or legal guardrails. KYOK Encryption FIPS 140-2 Level 4 HSM Ensures the provider—and only the provider—can access raw patient data. Open Source Stack Red Hat Enterprise Linux/OpenShift Predictable economics and the ability to re-host apps without re-platforming. The Agentic Pivot: Automating the Hospital Workflow In 2026, artificial intelligence is no longer an "optional bolt-on" but a part of the core day-to-day operating model. IBM’s agentic ecosystem, comprised of watsonx Orchestrate, IBM Bob, and IBM Concert, moves AI from episodic pilots to resilient, systemic infrastructure. This ecosystem allows organisations to manage "fleets" of specialised AI agents that handle thousands of tasks across the business. Case Study: Providence and Workflow Modernisation Providence, one of the largest health systems in the United States, collaborated with IBM Consulting to address the severe hiring shortages in nursing and caregiver roles. The collaboration utilized an AI-powered HR agent built on watsonx Orchestrate and integrated with Providence's existing systems. The results after eight months were transformative: Hiring Speed: Managers spent 90% less time on hiring steps, and internal transfers were accelerated by 12 days on average. Process Accuracy: Job requests created through the agent were 70% more accurate, reducing the need for costly downstream corrections. Economic Impact: The time to fill positions and the cost of transfers were both reduced by 60%, allowing Providence to get caregivers to the bedside significantly faster. This "workforce multiplier" effect is critical for an industry expecting 29% of its employees to require reskilling by 2028. By automating administrative toil, hospitals can redirect their human talent toward the high-value clinical interactions that define patient outcomes. The Human Side of Adoption IBM’s 2026 CEO Survey highlights that 83% of executives believe AI success is dependent on organizational adoption rather than the technology itself. This has led to the introduction of "Process Studio," a tool that helps enterprises convert legacy Standard Operating Procedures (SOPs) into agent-ready workflows. In a recent project, IBM used AI to analyse 1,400 procedures and uncover 1,000 improvement opportunities, projecting a 25% reduction in operating costs over 18 months. IBM is re-entering the healthcare space: Less "Jeopardy!" and more "Efficiency" Hardware and Performance: The Power of On-Chip AI IBM’s infrastructure differentiation hinges on the unique integration of hardware and software, bringing AI acceleration to where the data already lives. The z17 Mainframe and Spyre Accelerator The IBM z17 mainframe remains the unquestioned leader in secure, high-performance transaction processing. For healthcare finance and fraud detection, the z17 uses on-chip AI accelerators to run billions of inferences at sub-millisecond latency. This allows for the screening of 100% of billing transactions in real-time, rather than relying on sampled checks. The IBM Spyre Accelerator, made commercially available in late 2025, enables hospitals to scale generative and agentic AI workloads directly on their z17, LinuxONE, and Power systems. This hybrid architecture reduces the carbon footprint of AI workloads through high-density, energy-efficient designs that deliver higher performance per watt than traditional GPU-heavy clusters. Collaboration with NVIDIA and Arm To counter the dominance of public cloud hyperscalers, IBM has formed deep hardware alliances. The collaboration between Red Hat and NVIDIA aligns hybrid AI solutions with the NVIDIA AI stack, allowing enterprises to deploy AI-accelerated applications across any environment from the data centre to the public cloud using a unified, automated infrastructure. Simultaneously, IBM and Arm are developing dual-architecture hardware to help enterprises run future AI and data-intensive workloads with greater power efficiency. This ensures that hospitals have a choice in their silicon strategy while maintaining the reliability and security of mission-critical systems. The Quantum-AI Flywheel in Life Sciences IBM has positioned quantum computing not as a distant science project, but as a practical component of the 2026 research computing environment. The "quantum-and-AI flywheel" is a new paradigm where quantum systems solve complex molecular problems, such as protein folding and optimisation, that are mathematically impossible for classical compute, while AI models operationalise those findings for clinical use. The Cleveland Clinic Quantum Milestone In May 2026, researchers at Cleveland Clinic, RIKEN, and IBM announced the simulation of a 12,635-atom protein complex, the largest biological molecule ever modeled using quantum hardware. This simulation utilised the EWF-TrimSQD algorithm, which reduced computational overhead and increased accuracy by 210x compared to previous methods. Cleveland Clinic now operates its own IBM quantum computer on-site, using it to advance drug discovery, enzyme behavior modeling, and vaccine development. For hospital systems, this represents a transition to "Intelligent Research Operations," where the hybrid cloud provides the connective tissue between laboratory breakthroughs and the patient's bedside. Quantum Milestone Technical Achievement Industry Impact Protein Modeling 12,635-atom simulation Accelerating drug discovery for complex diseases like Alzheimer’s. Accuracy Gains 210x improvement in key steps Moving from theoretical results to clinically actionable data. Scaling Factor 40x increase in molecule size Enabling the study of larger, more biologically meaningful systems. Hybrid Workflow Integration of Quantum & AI AI agents operationalize quantum-discovered molecular structures. Comparative Analysis: IBM vs. The Hyperscalers in 2026 The healthcare cloud infrastructure market is characterised by a "three-way dynamic" among the hyperscalers, with IBM occupying a distinct, high-margin niche in regulated environments. Microsoft Azure: The Clinical Desktop Leader Microsoft remains the dominant force in the clinical interface layer, leveraging its $20 Billion acquisition of Nuance and its deep partnership with Epic. Microsoft’s DAX Copilot is the most widely deployed ambient documentation tool, processing over 500 Million clinical notes. Its primary advantage is native integration into Microsoft 365 and the Epic Hyperspace, making it the preferred "face" for frontline clinicians. AWS: The Scale and Flexibility Leader AWS maintains the largest overall cloud market share (approx. 31%) by offering unmatched scale and model diversity through Amazon Bedrock. Its healthcare-specific services, such as HealthLake and HealthScribe, provide developers with modular tools to build custom AI solutions. AWS is the default choice for hospitals that prioritize granular infrastructure control and global scalability. Google Cloud: The Analytical and Research Leader Google Cloud Platform (GCP) distinguishes itself through clinical AI model quality (MedLM) and petabyte-scale analytics via BigQuery. It has found success with research-heavy institutions like Seattle Children's, focusing on clinical decision support and complex differential diagnosis. Google also leads in multi-language support, which is a differentiator for health systems serving diverse patient populations. IBM: The Infrastructure and Sovereignty Challenger IBM’s strategy is not to compete on "model size theatrics" but to build the AI equivalent of enterprise middleware. IBM differentiates itself by acknowledging that "AI won't live in a single cloud". Its combination of on-premises capability, mainframe integration, and Sovereign Core governance is difficult for the hyperscalers to match in the regulated hybrid-enterprise space. While AWS and Azure support mature virtual machine estates, IBM Cloud is favoured by teams that require air-gapped deployment support and deep governance across the entire AI lifecycle. Feature Microsoft Azure AWS Google Cloud IBM Market Share ~25% ~31% ~11% Focused Niche Clinical Strength Epic/Nuance Integration Model Choice/Bedrock Analytical Accuracy Sovereignty/Mainframe Technical Edge Desktop UI Ecosystem Granular Control BigQuery Analytics Layer 8/MCP Plumbing Pricing Model Pay-as-you-go Serverless/PMPM Competitive/Transparent Subscription/Consumption Best For Microsoft-Native Custom Development Research-Intensive Regulated Infrastructure The Identity Governance Crisis: Managing the Non-Human Workforce A significant structural problem keeping healthcare AI stuck in the pilot phase in 2026 is identity governance. As hospitals deploy hundreds of specialised agents, for medical transcription, lab validation, and RCM, they generate non-human identities that most legacy IT systems cannot scope, inventory, or revoke at machine speed. This "visibility gap" has created a trust deficit, with only 5% of enterprise AI agents currently reaching production despite 85% participation in pilots. IBM has responded to this by integrating identity management for agents directly into the runtime layer of the AIOS. This ensures that when a medical transcription agent updates an EHR, the action is cryptographically verified and tied to a traceable identity, mitigating the risk of unauthorised access or AI-enabled vulnerability discovery. Implementation Strategy: The Move to "Low-Code" Efficiency Recognising that the technical complexity of AI can be a barrier to adoption, IBM has introduced several initiatives to simplify how hospitals procure and deploy automation. The eCommerce Pilot for AI Agents To remove friction from the "evaluation to production" path, IBM launched an eCommerce pilot that allows hospitals to purchase pre-vetted AI agents directly from IBM.com. These agents are bundled with watsonx Orchestrate subscriptions, allowing hospitals to access "proven AI agents" for tasks like insurance verification and data access without navigating complex multiple-vendor contracts. Pro-Code to Low-Code Visualisations IBM Consulting has expanded its "Consulting Advantage" platform to allow technical teams to view complex pro-code workflows as low-code visualisations. This supports faster debugging and lifecycle management, which is essential for hospital IT departments that are often under-resourced. Furthermore, the introduction of "IBM Bob" as an agentic development partner helps developers modernise legacy COBOL and mainframe code faster, resolving security risks as the code is written. Conclusions The re-emergence of IBM in the healthcare sector in 2026 is defined by a rigorous focus on "Efficiency" and the provision of a secure, hybrid-cloud foundation. By abandoning the high-risk endeavor of clinical tool development and doubling down on "neutral plumbing," IBM has addressed the specific pain points of a cash-strapped industry: margin pressure, workforce shortages, and regulatory uncertainty. The transition from "Jeopardy!" to "Efficiency" is a strategic acknowledgement that in a highly regulated, high-stakes domain like medicine, the most valuable technology is the one that operates reliably in the background, securing the data and automating the administrative toil that has long hindered the progress of digital healthcare. Strategic success for health systems in the next three years will be determined by their ability to treat AI not as a science project, but as core infrastructure. IBM’s blueprint for the AI Operating Model provides the necessary framework for this transition, offering hospitals the "peace of mind" required to scale AI safely and responsibly in the industrial era of medicine. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Whoop and the Future of the Quantified Self The Strategic Evolution of the Health Operating System: Clinical Integration and Generative AI in Wearable Technology The global health technology sector has entered a transformative phase characterised by the convergence of continuous biometric monitoring, generative artificial intelligence, and synchronous clinical care. This paradigm shift is most prominently evidenced by the recent strategic expansion of WHOOP, a human performance company that has historically focused on the optimisation of elite athletic performance but is now aggressively repositioning itself as a clinical-grade "Health Operating System". The introduction of on-demand telehealth services, advanced electronic health record (EHR) synchronisation, and a persistent AI context layer represents a direct challenge to the legacy model of episodic, snapshot-based healthcare. By bridging the gap between passive sensor data and active medical intervention, the industry is witnessing the maturation of the "quantified self" movement into a formal component of the healthcare continuum. The Synchronous Care Paradigm: In-App Telehealth and Clinical Oversight The cornerstone of the 2026 strategic update is the integration of live, on-demand video consultations with licensed clinicians directly within the mobile application environment. This feature, slated for a staggered rollout in the United States beginning in the summer of 2026, aims to solve the primary friction point in consumer wearables: the data-action gap. While modern sensors are capable of capturing high-fidelity streams of heart rate variability (HRV), resting heart rate (RHR), and blood oxygen saturation, most consumers lack the clinical literacy required to interpret these signals in the context of their medical history. Longitudinal Data vs. Episodic Snapshots The fundamental innovation of the telehealth integration lies in the presentation of longitudinal data to the clinician. Traditional primary care and urgent care visits rely on "brief, episodic snapshots," where vitals are measured at a single point in time, often under the influence of immediate stressors or the "white coat" effect. In contrast, the consultations facilitated by this new platform begin with a comprehensive dashboard encompassing months of continuous biometric history, as well as integrated bloodwork and medical records. This allows a physician to observe how physiological baselines react to specific interventions, such as the introduction of a new medication, changes in training load, or the onset of a chronic condition. For example, a clinician reviewing a member's profile can analyse how a specific pharmaceutical intervention for hypertension impacts the user's recovery score and cardiovascular strain over a thirty-day window. This temporal density of data transforms the clinical encounter from a reactive diagnosis of symptoms into a proactive management of health trends. The service is structured as a paid add-on, reflecting the high operational cost of maintaining a 24/7 network of licensed providers compared to purely algorithmic coaching. Technical Infrastructure and the Role of Synchronous Video The delivery of telehealth is supported by a sophisticated digital health infrastructure designed to handle high-bandwidth video streams alongside real-time data visualisation. Members initiate consultations through the application, where they are matched with virtual experts who can interpret complex biometric datasets. These clinicians have the authority to provide medical guidance, though the company has clarified that the service is intended to work alongside, rather than replace, primary care physicians or emergency services. Feature Component Implementation Status Infrastructure / Partner Regional Availability Video Consultations Launching Summer 2026 Undisclosed Clinician Network United States Only EHR Synchronisation Active/Q2 2026 HealthEx United States Only Advanced Labs Analysis Active Integrated Lab Partners United States Only Blood Pressure Insights Active (MG Only) Proprietary PPG/BPI Model US (subject to FDA 2026 guidance) ECG Heart Screener Active (MG Only) FDA-Cleared ECG Module US, EU, GCC (partial) The decision to launch exclusively in the United States initially is a strategic response to the complex landscape of state-level medical licensing and the specific telehealth reimbursement models prevalent in the American market. Technical Infrastructure: EHR Synchronisation and the HealthEx Partnership The efficacy of clinical telehealth depends heavily on the interoperability of the wearable platform with traditional healthcare systems. To facilitate this, the company has partnered with HealthEx, a unified health records platform, to enable secure Electronic Health Record (EHR) synchronisation. This integration allows members to push their clinical history, including diagnoses, medications and surgical procedures, directly into the application profile. The TEFCA Framework and Data Portability HealthEx utilises the Trusted Exchange Framework and Common Agreement (TEFCA) network, which is supported by the Center for Medicare and Medicaid Services (CMS) and covers more than 80% of healthcare providers in the United States. This network facilitates a seamless "patient-first" privacy model where the user maintains sovereignty over their data. Members must provide explicit consent for the synchronisation of their records, and they retain the ability to revoke access or edit specific data entries at any time. The implications of this synchronisation for clinical workflows are significant. By integrating EHR data with continuous biometrics, the platform can identify causal relationships that were previously obscured. A patient with a diagnosis of asthma, for example, can see exactly how a change in local air quality, detected via GPS and environmental data, correlates with a drop in respiratory rate or sleep quality. The AI coach and human clinicians can then provide personalised recommendations that account for these medical realities. Security Protocols and the Regulatory Gap While the HealthEx integration utilizes encryption and HIPAA-compliant frameworks for data transfer, industry observers have highlighted a persistent "regulatory gap" in the wearable sector. Under current U.S. law, consumer wearable companies are often not classified as "covered entities" under HIPAA unless they are acting as business associates for a healthcare provider. This means that biological signals collected by the device may receive fewer federal protections than those collected in a traditional clinical setting. The company has attempted to mitigate these concerns by emphasising that it "never sells" personal data and that all biometric metrics are anonymised before being processed by third-party large language models (LLMs) used for coaching. However, a 2025 class-action lawsuit (Lomeli v. Whoop) alleging unauthorised data sharing with a third-party tracker called Segment has forced the company to defend its privacy practices in court. The AI Context Layer: My Memory and Proactive Coaching Parallel to the clinical expansion is a significant evolution of the platform's artificial intelligence capabilities. The launch of "My Memory" and "Proactive Check-Ins" signals a move toward a generative AI model that is not only responsive but anticipatory. The My Memory Framework: Architecting Personal Context The "My Memory" feature acts as a persistent repository for qualitative context that sensor data alone cannot capture. The system organises this information into seven distinct categories, creating a multidimensional profile of the user's life. Goals: Short-term and long-term objectives, such as training for a specific race or improving sleep consistency. Identity: Foundational personal factors, including occupation, family status (e.g., "new parent"), and geographic location. Lifestyle: Established habits and routines, such as dietary preferences or specific workout times. Preferences: The desired tone and frequency of coaching, ranging from direct, concise feedback to educational support. Events: Upcoming disruptions to normal routine, such as travel, weddings, or medical procedures. Health History: Chronic conditions, past injuries, and ongoing medications that impact physiological baselines. Mood: Qualitative daily assessments of mental and emotional state. By layering this context over raw heart rate and sleep data, the AI Coach, powered by OpenAI’s GPT-4, can deliver highly nuanced guidance. For example, if the device detects a significant drop in recovery scores, the AI can cross-reference the user's "Memory" to see if they recently logged a "new parent" status or an upcoming international trip.Instead of issuing a generic warning about potential illness, the system can provide specific recommendations for managing sleep debt while traveling or caring for an infant. Proactive Check-Ins and Behavioural Accountability The transition from a reactive "dashboard" to a proactive "partner" is realised through the "Proactive Check-Ins" feature. Utilising push notifications, the system initiates conversations at "moments that matter most," such as before a key event or after a period of poor sleep. This move is designed to replicate the psychological accountability provided by a human coach. If a user has shared a goal of improving their morning routine, the AI may check in after a successful week to reinforce the behaviour, or flag if increased work stress, as detected through the Stress Monitor, is beginning to erode those habits.The system is designed to "stay quiet" when no action is warranted, ensuring that notifications remain relevant and avoid "alert fatigue". Hardware and Sensor Innovation: WHOOP 5.0 and the Medical Grade Sensor The software and AI updates are supported by a bifurcated hardware strategy. The company’s current lineup includes the WHOOP 5.0 and the WHOOP Medical Grade (MG) sensor, each catering to different levels of health intensity. The WHOOP 5.0: Miniaturisation and Battery Efficiency The WHOOP 5.0 represents a significant advancement in sensor housing and energy management. Despite being 7% smaller than its predecessor, the 5.0 delivers more than triple the battery life, reaching upwards of 14 days on a single charge. This is achieved through a redesigned photoplethysmography (PPG) sensor that provides cleaner heart rate signals and a more accurate accelerometer for activity classification. Hardware Feature WHOOP 4.0 WHOOP 5.0 / MG Dimensions 34.7mm x 24mm x 11.5mm 34.7mm x 24mm x 10.6mm Weight ~33 grams ~26.5 grams Battery Life 4-5 Days 14+ Days Waterproofing IP68 (10m) IP68 (10m) ECG Capability None MG Only (with Luxe band) Blood Pressure None MG Only A key technical challenge addressed in the 5.0 is the "wearability" of the device. The platform continues to leverage its "Any-Wear" apparel line, allowing the sensor to be moved from the wrist to other body locations, such as bras, boxers, or sleeves, while maintaining data integrity. However, the 5.0 introduces a redesigned buckle and charging system that is not backward-compatible with 4.0 accessories. The WHOOP MG and Clinical-Grade Metrics The WHOOP MG (Medical Grade) sensor is the exclusive hardware for the "Life" tier membership. This version includes the specific sensors required for on-demand ECG readings and "Blood Pressure Insights". To take an ECG, members must use a compatible band, such as the SuperKnit Luxe, which incorporates metal accents that act as electrodes. By placing a thumb and index finger on the clasp, the user can generate a snapshot of their heart's electrical activity, which is then analysed for signs of atrial fibrillation (AFib). The "Blood Pressure Insights" (BPI) feature utilises a proprietary model that estimates systolic and diastolic ranges during sleep. After an initial calibration with a traditional cuff, the system uses HRV, heart rate, and blood flow patterns to provide a morning estimate of blood pressure when the body is at rest. This is positioned as a wellness tool to help users understand how stress and recovery impact cardiovascular trends, rather than a diagnostic replacement for a clinical monitor. Regulatory Dynamics: The FDA Standoff and 2026 Wellness Guidance The push into clinical health has brought the company into direct friction with the U.S. Food and Drug Administration (FDA). In July 2025, the FDA issued a warning letter regarding the "Blood Pressure Insights" feature, asserting that it met the definition of a medical device requiring 510(k) clearance. The "Medical-Grade" Controversy The core of the regulatory dispute centred on the specific linguistics used in marketing. The company’s website originally described the BPI feature as delivering "medical-grade health and performance insights". The FDA argued that the term "medical-grade" implies clinical validation and diagnostic intent, which could lead consumers to rely on the device for the management of hypertension or hypotension. This standoff lasted approximately six months, during which the company maintained that BPI was a wellness feature designed for habit change and awareness. The impasse was largely resolved in January 2026, when the FDA released updated "General Wellness" guidance. This new framework established that non-invasive blood pressure estimations via optical sensing could remain in the wellness category, provided that companies make no claims of diagnostic accuracy and explicitly avoid terms like "medical-grade". Global Regulatory Variations While the company has secured FDA clearance for its ECG feature, regional availability remains dependent on local regulatory bodies. As of early 2026, ECG and IHRN (Irregular Heart Rhythm Notifications) are available in the U.S., EU and several GCC countries, but remain "pending" in territories such as Jersey, Guernsey, and the Isle of Man due to specific local health tech certifications. This creates a fragmented user experience for international travelers and highlights the challenges of scaling a regulated health platform globally. Market Competition: The Fitbit Air and Google Gemini Response The strategic timing of WHOOP's announcement, arriving exactly 24 hours after the launch of the Google Fitbit Air, indicates a fierce competitive battle for the "screen less" wearable market. Philosophical Divergence in Health Coaching The competition between Google and WHOOP represents a fundamental philosophical split in the industry. Google's approach with the $99 Fitbit Air is centred on the commoditisation of health interpretation. By integrating its Gemini-powered AI coach, Google aims to drive the cost of personalised health guidance toward zero through pure automation.The Gemini coach generates workout plans, summarises health records, and answers fitness questions without human oversight. WHOOP, conversely, is doubling down on a premium "human-in-the-loop" model. While its annual memberships are significantly more expensive ($199–$359), the inclusion of clinical consultations argues that the accountability of a human medical license is worth the price. Metric Google (Fitbit Air) WHOOP (Peak/Life) Hardware Cost $99 Included in Membership Subscription $99/year (Premium) $199 - $359/year AI Foundation Gemini (Google) GPT-4 (OpenAI) Interpretation Pure AI AI + Human Clinician Target Segment Mass Market / Budget Performance / Clinical Enthusiasts The industry analysis suggests that the Fitbit Air is a "defensive" threat to WHOOP's market share, particularly among users who prioritise a lower price point over high-touch clinical services. However, the company maintains a loyal base of approximately 2.5 Million users who are "locked in" to its high-fidelity data ecosystem. Whoop and the Future of the Quantified Self Intellectual Property and Legal Challenges: Trade Dress and Data Privacy As the digital health space becomes increasingly crowded, the company has turned to the legal system to protect its market position. Defending the "Moat": WHOOP v. Bevel and Lexqi In March 2026, the company filed a trade dress infringement lawsuit against Bevel, a startup health analytics app. The suit alleges that Bevel copied the "look and feel" of the platform, including the specific visual organisation of recovery, strain, and sleep metrics. This is a rare instance of trade dress doctrine being applied to digital user interfaces (UI) rather than physical packaging. The company also secured a preliminary injunction against Shenzhen Lexqi Electronic Technology, a Chinese manufacturer. The federal court ordered Lexqi to halt U.S. sales of a wearable that was deemed to be an infringing copy of the "iconic" screenless fabric band design. These legal actions indicate a strategy of reinforcing "moats" through litigation as the functional features of wearables become harder to differentiate. Privacy and the California Class Action The company’s data practices remain under scrutiny due to multiple active class-action lawsuits. Lomeli v. WHOOP (2025): Alleges unauthorised sharing of sensitive biometric data with Twilio’s Segment tracker. Sanderson v. WHOOP (2023): Alleges deceptive enrolment and renewal practices in violation of California's Automatic Renewal Law. Rowe v. WHOOP (2025): Targets allegedly false advertising of "medical-grade" blood pressure insights. The Lomeli case is particularly problematic as it alleges that granular data, including stress levels, sleep patterns, and even video-watching history within the app, was transmitted to third parties without consent. This creates a tension between the company’s "we never sell data" marketing and the technical realities of using third-party SDKs for app analytics. Business Strategy and Financial Outlook: Funding, Hiring, and the IPO Roadmap The expansion into clinical care is supported by a massive capital infusion that positions the company for a transition to the public markets. Series G and the $10.1 Billion Valuation In late March 2026, the company announced a $575 Million Series G funding round at a $10.1 Billion valuation. The round was led by Collaborative Fund and included strategic investments from the Qatar Investment Authority (QIA), Mubadala Investment Company and importantly, healthcare heavyweights like Abbott and the Mayo Clinic. The participation of Abbott and the Mayo Clinic underscores a "strategic alignment" with mainstream medicine, lending clinical credibility to the company’s aspirations. The 2026 Hiring Surge To support this growth, the company announced plans to add over 600 new roles in 2026 across software, research, hardware, and marketing. The majority of these roles will be based at the Boston headquarters, with additional hiring in Europe, the GCC, and Asia. CEO Will Ahmed has framed this expansion as a dual investment in "exceptional talent and world-class AI tools" to own the "Health Operating System" category. IPO Speculation and Global Pricing Dynamics The Series G round is widely believed to be the company’s final private funding before a public debut. This trajectory has led to concerns among some members that a post-IPO focus on quarterly earnings could lead to price increases or a degradation in service quality. Region Membership Tier Hardware Version Annual Renewal (USD/GBP) USA One / Peak / Life 5.0 / MG $199 - $359 UK One / Peak / Life 5.0 / MG £155 - £359 EU One / Peak / Life 5.0 / MG €199 - €359 GCC / Asia One 4.0 (CPO) Variable In the United Kingdom, athletes often face significant markups and stock delays compared to the U.S. market, leading to a vibrant secondary market for importing U.S. hardware to save upwards of £115 per year. This highlights a "strategic error" in the international rollout, as fans in London and Manchester often wait months for inventory that is plentiful in U.S. warehouses. Conclusion: The Future of the Quantified Self The transformation of the wearable fitness tracker into a clinical health platform marks a decisive shift in how individuals and the medical community interact with personal health data. The integration of synchronous telehealth, generative AI, and EHR synchronisation suggests that the "Quantified Self" movement is graduating from a hobbyist pursuit to a formal medical utility. The architectural shift from reactive monitoring to proactive guidance, facilitated by the "My Memory" framework and the clinical interpretation of longitudinal biometrics, addresses the long-standing criticism that wearables provide data without context. By positioning the AI as a "physician’s assistant" rather than a replacement for human medical expertise, the company is navigating a middle path that balances the efficiency of algorithms with the accountability of medical licensing. However, the path forward is fraught with regulatory and legal risks. The standoff with the FDA and the ongoing privacy class actions underscore the vulnerability of health tech companies operating in the "regulatory gap" between consumer gadgets and regulated medical devices. Furthermore, the aggressive competition from Google and the Fitbit Air suggests a period of intense pricing pressure that may force a choice between high-touch human care and affordable algorithmic health. As the company moves toward an anticipated IPO in 2026, its ability to maintain high standards of data security while scaling its clinical offerings will be the ultimate determinant of its long-term viability. The evolution of the platform from a "strap" to a "Health Operating System" represents a gamble that the future of medicine is continuous, conversational, and deeply personalized. The success of this model will likely establish the blueprint for the next generation of digital health ecosystems worldwide. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Digital Health and HealthTech IPO Performance Analysis The landscape of healthcare technology and digital health equity markets from late 2024 through mid-2026 has been characterised by a structural revaluation that industry analysts define as the emergence of "Health Tech 2.0". This transition represents a definitive pivot away from the speculative, growth-at-all-costs models of the 2015 to 2021 era, frequently termed Health Tech 1.0, which were often defined by poor unit economics and a reliance on pandemic-driven temporary tailwinds. The new cohort of companies that have entered the public markets in the last 12 to 24 months, including Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health and Kestra Medical, are distinguished by significantly more robust business metrics, including a clear path to profitability, deeply embedded artificial intelligence infrastructure and clinical-grade evidence that justifies their inclusion in standard medical workflows. The collective performance of these stocks in 2025 demonstrated a "comeback story" for the sector, with the Health Tech 2.0 cohort adding approximately $36.6 Billion in fresh market capitalisation. This cohort rose by an average of 18% during 2025, matching the gains of the S&P 500 and the NASDAQ Composite, and notably eclipsing the 7% decline observed in the Nasdaq Emerging Cloud Index. However, as the market progressed into the first half of 2026, the performance of individual entities within this group became highly bifurcated. Investors began to differentiate between companies achieving "Infrastructure Grade" status, those with high net revenue retention and software like margins and those facing traditional healthcare service headwinds or valuation compression due to lingering skepticism from previous market cycles. Comparative Performance and Valuation Metrics of the 2024-2025 IPO Cohort The 2024-2025 IPO class has been subjected to rigorous fundamental analysis, with the market increasingly applying the "Rule of 40" (the sum of revenue growth and free cash flow margin) and "ARR per FTE" (annual recurring revenue per full-time employee) as primary barometers of value. The following data highlights the performance and valuation dispersion across the six primary companies of interest as of May 2026. Equity Performance and Market Valuation Summary Company Ticker IPO Date IPO Price Current Price (May 2026) Performance Since IPO Market Cap (May 2026) Tempus AI TEM June 14, 2024 $37.00 $48.46 +31.0% $8.84B Waystar WAY June 7, 2024 $21.50 $21.38 -0.5% $3.82B Hinge Health HNGE May 22, 2025 $32.00 $55.00 +71.9% $4.24B Omada Health OMDA June 6, 2025 $19.00 $14.58 -23.3% $0.87B Caris Life Sciences CAI June 18, 2025 $21.00 $16.15 -23.1% $4.57B Kestra Medical KMTS March 6, 2025 $17.00 $21.83 +28.4% $0.84B Data reflects closing prices and market capitalisation figures recorded between May 7 and May 11th, 2026. The performance indicates that specialised medtech (Kestra) and high-margin, AI-driven platforms (Hinge Health, Tempus AI) have outperformed, while chronic care platforms (Omada Health) and molecular profiling services (Caris Life Sciences) have faced a post-IPO cooling period despite robust operational growth. This bifurcation is further reflected in the "Health AI X Factor" framework, which assigns premium valuations to companies capable of achieving unprecedented growth through AI-native automation. Efficiency and Growth Benchmarks (FY 2025 - Q1 2026) Company EV / Revenue (2026E) Revenue Growth (YoY) FCF Margin Rule of 40 Score ARR per FTE (Est.) Hinge Health 5.7x 72% 26% 98 $500K - $1M Tempus AI 9.3x 85% -22% 63 $400K - $600K Caris Life Sciences 8.9x 117% -7% 110 $350K - $500K Waystar 6.9x 12% 27% 39 $250K - $400K Omada Health 2.5x 65% -1% 64 $300K - $450K Sector Average 7.2x 67% -2% 65 $400K - $700K Comparison against typical cloud benchmarks where Rule of 40 average is 38 and ARR per FTE for non-AI SaaS is $200K-$400K. The analysis of these metrics suggests that while the Health Tech 2.0 cohort demonstrates significantly higher sustainability than the broader cloud index, they continue to trade at a 10–20% "trust gap" discount. This discount is attributed to the market's need for continued validation of AI's ability to drive long-term operating leverage in clinical settings. Tempus AI: The Data-Centric Valuation Leader Tempus AI, listing on the NASDAQ on June 14, 2024, under the ticker TEM, has served as a central pillar of the AI-native healthcare narrative. The company’s share price has followed a volatile but ultimately rewarding trajectory for long-term investors. After an IPO price of $37.00, the stock experienced a significant surge in late 2025, reaching an all-time high of $103.25 in October 2025. This peak was driven by the market's realisation of the value of Tempus’s proprietary datasets, which integrate clinical and genomic information for over seven million patients. As of May 2026, the stock has settled at approximately $48.46, with a market capitalization of $8.84 billion. While the price has retraced from its 2025 highs, the company maintains a 31% gain over its IPO price, outperforming many of its peers in the broader digital health sector. The recent trading history in April and May 2026 shows a period of consolidation. Between April 13 and April 15, 2026, the stock jumped from $45.98 to $56.41, a reaction to positive sentiment surrounding its molecular profiling scale and its inclusion among the largest companies by market capitalisation in its sector. Tempus AI's strategic value is derived from its "data moat," which enables it to achieve high revenue growth (85%) even as it invests heavily in FCF-negative operations (-22% margin). This "Health AI X Factor" is particularly relevant in the context of drug discovery, where Tempus’s data is increasingly utilised by pharmaceutical companies to identify novel biomarkers and optimise clinical trials. The market currently rewards this data-heavy approach with one of the highest EV/Revenue multiples in the cohort at 9.3x. Waystar Holding: Navigating 52-Week Lows Amid Strategic Integration Waystar (Nasdaq: WAY), which listed in June 2024, provides a starkly different performance narrative. Despite being a leader in revenue cycle management (RCM) technology, the stock has struggled to maintain its valuation in the face of shifting analyst sentiment and technical resistance. In early May 2026, Waystar’s stock hit a series of 52-week lows, trading as low as $19.77, which is slightly below its estimated IPO price of $21.50. This downturn occurred despite the company reporting strong financial results for the first quarter of 2026. Waystar surpassed expectations with revenue of $313.9 million, representing 22% year-over-year growth. Subscription revenue, a key driver for long-term valuation, grew by 38%, and adjusted EBITDA increased by 26%. However, the market’s focus has been on the downward revision of forward consensus EPS estimates. In early 2026, the consensus outlook for the fiscal year 2026 EPS was lowered from $0.97 to $0.839, leading to a reduction in the average price target from approximately $46.00 to between $37.00 and $38.27. Waystar Financial and Strategic Indicators (May 2026) Metric Value Significance Market Capitalisation $3.82B - $4.14B Reflects a 50.3% loss from the 52-week high of $41.49. EV / EBITDA 12.4x Relative good value compared to peer average of 14x-18x for AI platforms. Debt-to-Equity 0.66 Manageable leverage after the $1.1B acquisition of Iodine Software. Institutional Ownership 74.9% Dominance of BlackRock, Bain Capital, and EQT suggests long-term backing. The primary driver for Waystar’s future recovery is the deployment of its AltitudeAI platform, which targets "silent denials", payer recoupments that represent an estimated $40 Billion in annual provider revenue loss. The company’s acquisition of Iodine Software in late 2025 for $1.1 Billion is progressing ahead of schedule and is expected to contribute significantly to cross-selling into clinical and financial workflows by 2027. Analysts remain divided, with TD Cowen maintaining a "Buy" rating and a $42.00 price target based on valuation, while UBS trimmed its target to $37.00 citing "guidance cadence". Hinge Health: The Outperformer of the 2025 Class Hinge Health (NYSE: HNGE) has emerged as the clear performance leader of the 2025 IPO class. Pricing its IPO at $32.00 on May 21, 2025, the company’s shares surged immediately, closing at $37.56 on the first day of trading. By May 2026, Hinge Health shares have climbed to $55.00, representing a 71.9% increase from the IPO price. The stock's momentum is backed by a "Rule of 40" score of 98, the highest in the cohort, driven by 72% revenue growth and a 26% FCF margin. The company’s Q1 2026 results were a significant catalyst for this momentum. Hinge reported revenue of $182 Million, a 47% year-over-year increase that surpassed its own guidance of $171 Million to $173 million. More importantly, the company demonstrated massive operating leverage; gross margins reached 85%, and non-GAAP income from operations grew by 208% to $46.2 Million. Hinge Health’s success is attributed to its "non-commodity" hardware component, the Enso neuromodulation device, which was recently cleared by the FDA for the treatment of migraines. This expansion beyond musculoskeletal (MSK) care into a condition affecting one in six American adults represents a significant addressable market expansion. The company’s move into migraine care is already seeing adoption by over 125 clients, representing more than two million eligible lives. Hinge Health Capital and Operational Efficiency (Q1 2026) Metric Q1 2026 Q1 2025 YoY Change Revenue $182M $123.8M +47% Gross Margin 85% 81% +400 bps Free Cash Flow $41.6M $4.2M +890% Cash on Hand $407M $500M (Q3 2025) Reflects $105M share buyback Client Count 2,849 2,311 +23% Hinge Health’s ability to maintain high gross margins while doubling the distribution of its Enso hardware as a percentage of its member base is a key differentiator. The company utilises AI to enhance care team efficiencies, offsetting the costs of physical device production. Furthermore, the company authorised a $250 Million share repurchase program in November 2025, signalling management's belief in the stock's intrinsic value and reducing the diluted share count by 2.5% in Q1 2026. Omada Health: Member Scale vs. Valuation Compression Omada Health (Nasdaq: OMDA) priced its IPO at $19.00 on June 6th, 2025, raising $150.1 Million. Despite achieving significant operational milestones, the stock has struggled in the public market, trading at $14.58 as of May 11th, 2026. This represents a 23.3% decline from its listing price, positioning it as one of the relative under-performers of the cohort in terms of share price appreciation. However, Omada’s financial trajectory has seen a fundamental improvement in 2026. In its Q1 2026 results, the company reported reaching 1.025 Million total members, a 51% year-over-year increase. Revenue reached $78 Million, up 42% from $55 Million in Q1 2025. Most notably, Omada achieved a key profitability milestone by reporting its first quarterly adjusted EBITDA of $1 Million, compared to a loss of $4 Million in the previous year. The disconnect between Omada’s performance and its share price is largely a function of its valuation multiple. Trading at only 2.5x EV/Revenue, the market appears to be valuing Omada more as a traditional chronic care provider than an AI-driven technology platform. This is despite the company’s extensive data infrastructure, which processes 75,000 data points every hour and has recorded over 130 Million blood glucose readings. Omada’s strategic positioning in the GLP-1 medication market is its most potent growth catalyst for 2026. The company’s GLP-1 Care Track has demonstrated that members lose 1.8 times the total weight and more than double the percentage of body fat compared to a control group. By partnering with all three major US PBMs—Express Scripts, CVS Caremark, and now Optum Rx—Omada has secured a massive distribution channel for its cardio-metabolic suite of programs. Caris Life Sciences: Molecular Profiling at a Break-Even Inflection Caris Life Sciences (Nasdaq: CAI) represents the high-beta segment of the Health Tech 2.0 cohort. After completing its IPO on June 18, 2025, at $21.00 per share, the stock has faced volatility, trading at $16.15 by May 12, 2026. Like Omada, Caris has seen its share price decline by over 23% from its IPO price, yet its top-line growth remains the highest in the group. In Q1 2026, Caris reported a staggering 79% increase in total revenue to $216.2 Million. This growth was driven primarily by an 85% increase in Molecular Profiling Services revenue. The company’s gross margins improved from 47% to 65%, and it achieved a break-even EPS of $0.00 for the quarter, significantly exceeding analyst expectations of a $0.12 loss. Caris’s competitive advantage lies in its Whole Exome Sequencing (WES) technology, which it markets as superior to the targeted gene panels used by competitors. A study published by the company in May 2026 showed that WES-measured tumor mutational burden (TMB) was discordant with targeted panel estimates in 10-15% of cases, with WES more accurately predicting survival in pembrolizumab-treated patients. This clinical-grade evidence is crucial for the company's long-term adoption in oncology workflows. Caris Life Sciences Capital Structure and Insider Activity (May 2026) Attribute Value Context Market Capitalisation $4.57B - $5.61B Significant reset from the $7.83B private valuation. Cash from Operations $32.9M 205% improvement from the ($31.3M) used in Q1 2025. Total Revenue Guidance $1.0B - $1.02B Reaffirmed for full year 2026, representing 23-26% growth. Insider Buying $501,426 Director Jeff Vacirca purchased 31,050 shares at ~$16.15 in May 2026. Caris has also taken steps to stabilise its balance sheet, refinancing a $400 Million credit facility at a lower borrowing cost and securing strategic capital from Blue Owl and Blackstone. This refinancing, coupled with insider buying from board members, suggests a valuation floor may be forming as the company approaches consistent profitability. Kestra Medical: Niche Medtech Performance Kestra Medical (Nasdaq: KMTS) listed on March 6, 2025, pricing its upsized IPO at $17.00. By May 2026, the stock has appreciated to $21.83, a 28.4% increase that makes it one of the stronger performers in the medtech segment of the cohort. Kestra has benefited from its specialised focus on the wearable cardioverter defibrillator (WCD) market, where its ASSURE WCD has been worn by more than 17,000 patients. The company’s Q3 FY2026 results (ended January 31, 2026) showed 63% year-over-year revenue growth to $24.6 million. Kestra’s gross margin reached 52.6%, up from 43.4% in the previous year, and the company raised its full-year 2026 revenue guidance to $93 million. This specialised medtech success highlights a broader market trend: investors are rewarding companies with defined, highly regulated products that possess "compliance moats". The "Health AI X Factor" and the Productivity Transformation A primary insight derived from the performance of the Health Tech 2.0 cohort is the emergence of AI as a fundamental valuation multiplier. The "Health AI X Factor" framework distinguishes companies that achieve superior growth by shifting from the mere digitisation of manual workflows to the actual reduction of cognitive workloads. In 2026, AI-native healthcare companies are achieving $100M to $200M in ARR in under five years—nearly twice the speed of previous healthcare software generations. This efficiency is measured by the ARR per FTE metric, which has evolved as follows: Traditional Healthcare Services: $100K–$200K ARR per FTE. Healthcare SaaS (Pre-AI): $200K–$400K ARR per FTE. AI-Native Healthcare (2026): $500K–$1M+ ARR per FTE. Companies like Hinge Health and Tempus AI exemplify this shift. Hinge uses its "Robin" AI and automation tools to increase clinician throughput, while Waystar’s agentic AI network has reduced reconciliation times by 80%. This productivity leap allows these companies to maintain high gross margins (65%–85%) while operating at a scale that was previously labor-prohibitive. Macroeconomic Sentiment and Thematic Market Drivers The broader equity market environment in early 2026 has been defined by a "Great Rebalancing". After several years where technology and AI infrastructure dominated, the healthcare sector emerged as a primary engine of growth in the final quarter of 2025 and the first half of 2026. The "Warsh Shock" and Early 2026 Volatility The market experienced a significant "technological shock" in early February 2026, often referred to as the "Warsh Shock". On February 3rd and 4th, the tech-heavy Nasdaq fell 1.4%, and the S&P 500 slid 0.8% as investors rotated away from high-beta growth names toward defensive assets. During this period, healthcare technology and digital health ETFs like HTEC and EDOC experienced total declines of approximately 7.9% over a 10-day period. However, the recovery for Health Tech 2.0 names was supported by their "Infrastructure Grade" status. By late April 2026, the healthcare sector had become the best-performing sector quarter-to-date, up 7% compared to the S&P 500’s 1% gain. This recovery was driven by clarification around earnings and the easing of policy headwinds as the market digested the first few months of the new US administration. The Impact of the MAHA Agenda The "Make America Healthy Again" (MAHA) agenda, a central theme of the second Trump administration, has introduced new deregulatory tailwinds that favor sector consolidation. This "laissez-faire" approach to antitrust has facilitated a resurgence in mergers and acquisitions (M&A) activity. With major pharmaceutical companies facing a "patent cliff", the $300 Billion in revenue at risk from expirations by 2030—there is significant "dry powder" (over $1 trillion) being deployed to acquire innovative medtech and biotech firms. MAHA Priority Voter Support (MAHA) Impact on Healthtech Stocks Lowering Health Costs 42% Drives adoption of RCM (Waystar) and value-based care (Omada). Restricting Food Additives 21% Bolsters platforms focused on metabolic health and weight loss. Vaccine Policy Re-eval 10% Increases focus on personalized medicine and genetic screening (Tempus, Caris). Deregulation / Laissez-faire High (Admin) Facilitates consolidation and M&A for mid-cap healthtech names. While public opinion on MAHA priorities is divided, the cost of healthcare remains the primary motivator for voters across all parties, ensuring a bipartisan appetite for technologies that improve system efficiency. International Expansion and Regulatory Harmonisation The 2025–2026 period has seen a major breakthrough in UK-US regulatory cooperation, which has material implications for companies like Hinge Health and Tempus AI that are pursuing global expansion. The UK-US Economic Prosperity Deal In December 2025, the UK and US signed an Economic Prosperity Deal that includes a three-year commitment to 0% tariffs on pharmaceutical and medical technology exports. This deal is especially beneficial for UK-based medtech firms and US innovators expanding into Europe. Additionally, the UK reduced the "clawback tax" (VPAG payment) that companies pay the NHS from 23% to 15%, improving the profitability of international product launches. NICE Reform and Healthtech Evaluation On October 1st, 2025, the UK’s National Institute for Health and Care Excellence (NICE) expanded its evaluation program to put digital health and diagnostics on an equal footing with medicines. This "Healthtech Evaluation Programme" aims to end "postcode lottery" access to treatment, ensuring that recommended AI diagnostics and digital tools are implemented NHS-wide. Furthermore, the NICE cost-effectiveness threshold is set to increase from its 20-year range of £20,000–£30,000 to £25,000–£35,000 per QALY gained, effective April 2026. This adjustment provides greater "headroom" for premium-priced innovative technologies and is expected to convince global pharmaceutical and healthtech companies to prioritise the UK in their launch sequences. Institutional Ownership and Market Sentiment Analysis The ownership structure of the Health Tech 2.0 cohort remains heavily institutional, providing a degree of stability despite retail-driven volatility. Waystar, for instance, is 74.9% owned by institutions and 24.2% by VC/PE firms. The presence of top-tier investors like the Canada Pension Plan Investment Board (9.92%), BlackRock (8.58%), and Bain Capital (7.36%) indicates strong conviction in the long-term value of the revenue cycle automation model. However, there has been notable insider selling in the broader sector as share prices have surged in early 2026. For example, Gabriel Mecklenburg, Executive Chairman and Co-Founder of Hinge Health, sold 50,000 shares (valued at $2.75 Million) in May 2026 as the stock traded at a premium. Conversely, insider buying at Waystar and Caris Life Sciences suggests that management in those companies views their current stock prices as undervalued relative to their fundamentals. Future Outlook: Healthtech Infrastructure in late 2026 The strategic focus for digital health in the second half of 2026 is shifting from "experimentation" to "infrastructure". The winners of this next phase will be companies that resemble utilities: trusted pipes, models, and reimbursement mechanisms that are deeply embedded into the healthcare system. Key Predictions for the 2026/2027 Cycle Clinical-Grade Wearables: Consumer health data is becoming clinical-grade, as wearables are pulled into regulated workflows and procurement frameworks (e.g., Kestra Medical's integration into hospital WCD protocols). GLP-1 Stability: The initial hype around obesity medications is giving way to a focus on durable outcomes. Companies like Omada Health that pair medication with lifestyle coaching will be rewarded for long-term adherence metrics. AI ROI Mandate: By the end of 2026, AI will no longer be treated as a pilot. Hospitals and payers will expect a positive ROI for all AI applications, and those unable to provide tangible evidence of cost savings or clinical throughput will face valuation compression. M&A Consolidation: The "patent cliff" and favoUrable antitrust environment will likely lead to a series of high-value acquisitions in the oncology (Tempus/Caris) and MSK (Hinge) segments. In summary, the share prices of the digital health and healthtech companies that have IPOed in the last 12-18 months reflect a broader market rebalancing. While Hinge Health and Tempus AI represent the high-margin, data-rich winners of the current cycle, the operational progress at Waystar, Omada Health and Caris Life Sciences suggests that the valuation gap between "Health Tech 2.0" and the broader technology market is likely to close as these firms prove their durability in a complex regulatory and economic landscape. The sector's transition from speculative innovation to infrastructure-grade performance marks a structural turning point that promises to redefine the financial and clinical standards of the healthcare industry for the next decade. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk